BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Debast SB, Bauer MP, Kuijper EJ;  European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 Suppl 2:1-26. [PMID: 24118601 DOI: 10.1111/1469-0691.12418] [Cited by in Crossref: 692] [Cited by in F6Publishing: 607] [Article Influence: 86.5] [Reference Citation Analysis]
Number Citing Articles
1 Spigaglia P, Barbanti F, Morandi M, Moro ML, Mastrantonio P. Diagnostic testing for Clostridium difficile in Italian microbiological laboratories. Anaerobe 2016;37:29-33. [PMID: 26555737 DOI: 10.1016/j.anaerobe.2015.11.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
2 Candel-PÉrez C, Santaella-Pascual J, Ros-Berruezo G, MartÍnez-GraciÁ C. Occurrence of Clostridioides (Clostridium) difficile in Poultry Giblets at Slaughter and in Retail Pork and Poultry Meat in Southeastern Spain. J Food Prot 2021;84:310-4. [PMID: 33513258 DOI: 10.4315/JFP-20-256] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, Cornely OA, Buitrago M, Best E, Sambol S, Osmolski JR, Kracker H, Locher HH, Charef P, Wilcox M. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother 2016;71:213-9. [PMID: 26433782 DOI: 10.1093/jac/dkv300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
4 Madar PC, Petre O, Baban A, Dumitrascu DL. Medical students' perception on fecal microbiota transplantation. BMC Med Educ 2019;19:368. [PMID: 31601212 DOI: 10.1186/s12909-019-1804-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Guery B, Berger P, Gauzit R, Gourdon M, Barbut F, Dafne Study Group, Bémer P, Bessède E, Camou F, Cattoir V, Couzigou C, Descamps D, Dinh A, Laurans C, Lavigne JP, Lechiche C, Leflon-Guibout V, Le Monnier A, Levast M, Mootien JY, N'Guyen Y, Piroth L, Prazuck T, Rogeaux O, Roux AL, Vachée A, Vernet Garnier V, Wallet F; DAFNE study group. A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. J Int Med Res 2021;49:3000605211021278. [PMID: 34162264 DOI: 10.1177/03000605211021278] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rubio-Terrés C, Aguado JM, Almirante B, Cobo J, Grau S, Salavert M, González Antona Sánchez E, López Gutiérrez C, Rubio-Rodríguez D. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. Eur J Clin Microbiol Infect Dis 2019;38:1105-11. [PMID: 30989419 DOI: 10.1007/s10096-019-03503-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
7 Nowak A, Hedenstierna M, Ursing J, Lidman C, Nowak P. Efficacy of Routine Fecal Microbiota Transplantation for Treatment of Recurrent Clostridium difficile Infection: A Retrospective Cohort Study. Int J Microbiol 2019;2019:7395127. [PMID: 31354831 DOI: 10.1155/2019/7395127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
8 Thabit AK, Nicolau DP. Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection. Infect Dis (Auckl) 2015;8:1-4. [PMID: 25780339 DOI: 10.4137/IDRT.S23079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Stallmach A, Katzer K, Reuken P. [Non-severe Clostridioides difficile Infection: Are the data adequate to give up metronidazole?]. Z Gastroenterol 2020;58:778-84. [PMID: 32785914 DOI: 10.1055/a-1190-5735] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Igarashi Y, Tashiro S, Enoki Y, Taguchi K, Matsumoto K, Ohge H, Suzuki H, Nakamura A, Mori N, Morinaga Y, Yamagishi Y, Yoshizawa S, Yanagihara K, Mikamo H, Kunishima H. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. J Infect Chemother 2018;24:907-14. [PMID: 30170735 DOI: 10.1016/j.jiac.2018.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
11 Morinaga Y, Akamatsu N, Matsuda J, Tateno H, Tomaru T, Tanaka A, Morita S, Nakamura M, Kato H, Annaka M, Masuda Y, Itakura Y, Inamatsu T, Yanagihara K. Diagnostic utilities of a fully automated molecular test for toxigenic Clostridium difficile. Journal of Infection and Chemotherapy 2018;24:88-91. [DOI: 10.1016/j.jiac.2017.09.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Krutova M, Kinross P, Barbut F, Hajdu A, Wilcox MH, Kuijper EJ; survey contributors. How to: Surveillance of Clostridium difficile infections. Clin Microbiol Infect 2018;24:469-75. [PMID: 29274463 DOI: 10.1016/j.cmi.2017.12.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
13 Reigadas E, Muñoz-Pacheco P, Vázquez-Cuesta S, Alcalá L, Marín M, Martin A, Bouza E. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients. Anaerobe 2017;48:269-72. [PMID: 28988773 DOI: 10.1016/j.anaerobe.2017.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
14 Pellissery AJ, Vinayamohan PG, Kuttappan DA, Mishra N, Fragomeni BO, Maas K, Mooyottu S, Venkitanarayanan K. Protective Effect of Baicalin against Clostridioides difficile Infection in Mice. Antibiotics (Basel) 2021;10:926. [PMID: 34438975 DOI: 10.3390/antibiotics10080926] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Jørgensen SMD, Erikstrup C, Dinh KM, Lemming LE, Dahlerup JF, Hvas CL. Recruitment of feces donors among blood donors: Results from an observational cohort study. Gut Microbes 2018;9:540-50. [PMID: 29617178 DOI: 10.1080/19490976.2018.1458179] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
16 Monteiro CRAV, do Carmo MS, Melo BO, Alves MS, Dos Santos CI, Monteiro SG, Bomfim MRQ, Fernandes ES, Monteiro-Neto V. In Vitro Antimicrobial Activity and Probiotic Potential of Bifidobacterium and Lactobacillus against Species of Clostridium. Nutrients 2019;11:E448. [PMID: 30795551 DOI: 10.3390/nu11020448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 7.7] [Reference Citation Analysis]
17 Zhang VRY, Woo ASJ, Scaduto C, Cruz MTK, Tan YY, Du H, Feng M, Siah KTH. Systematic review on the definition and predictors of severe Clostridiodes difficile infection. J Gastroenterol Hepatol 2021;36:89-104. [PMID: 32424877 DOI: 10.1111/jgh.15102] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization With Toxinogenic C. difficile Upon Hospital Admission, and Risk of Infection: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2015;110:381-90. [DOI: 10.1038/ajg.2015.22] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 18.1] [Reference Citation Analysis]
19 Lauda-Maillen M, Liuu E, Catroux M, Caupenne A, Priner M, Cazenave-Roblot F, Burucoa C, Ingrand P, Paccalin M. Treatment compliance with European guidelines and prognosis of Clostridium difficile infection according to age. Med Mal Infect 2019;49:173-9. [PMID: 30266433 DOI: 10.1016/j.medmal.2018.08.001] [Reference Citation Analysis]
20 Oppfeldt AM, Dahlerup JF, Christensen LA, Hvas CL. Faecal microbiota transplantation for recurring Clostridium difficile infection in a patient with Crohn's disease and ileorectal anastomosis. BMJ Case Rep 2016;2016:bcr2016217209. [PMID: 27664230 DOI: 10.1136/bcr-2016-217209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Crowther GS, Wilcox MH. Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm. Infect Drug Resist 2015;8:333-7. [PMID: 26396535 DOI: 10.2147/IDR.S87224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
22 Fashandi AZ, Wang PT, Hedrick TL, Friel CM, Hays RA, Hallowell PT. Recurrent Clostridium difficile Infection after Diverting Loop Ileostomy and Colonic Lavage: An Unreported Complication of the Novel Surgical Therapy. The American Surgeon 2017;83:335-8. [DOI: 10.1177/000313481708300825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wu MA, Leidi F; On behalf of Gruppo di Autoformazione Metodologica (GrAM). Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality. Intern Emerg Med 2017;12:871-2. [DOI: 10.1007/s11739-017-1710-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Fehér C, Mensa J. A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management. Infect Dis Ther 2016;5:207-30. [PMID: 27470257 DOI: 10.1007/s40121-016-0122-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
25 Lomeli BK, Galbraith H, Schettler J, Saviolakis GA, El-Amin W, Osborn B, Ravel J, Hazleton K, Lozupone CA, Evans RJ, Bell SJ, Ochsner UA, Jarvis TC, Baqar S, Janjic N. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrob Agents Chemother 2019;64:e01395-19. [PMID: 31685472 DOI: 10.1128/AAC.01395-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
26 Gutiérrez-pizarraya A, Martín-villén L, Alcalá-hernández L, Marín Arriaza M, Balandín-moreno B, Aragón-gonzález C, Ferreres-franco J, Chiveli Monleón MÁ, Anguita-alonso P, Bouza-santiago E, Garnacho-montero J. Epidemiology and risk factors for Clostridium difficile infection in critically ill patients in Spain: The PROCRID study. Enfermedades Infecciosas y Microbiología Clínica 2018;36:218-21. [DOI: 10.1016/j.eimc.2017.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Martínez-Meléndez A, Camacho-Ortiz A, Morfin-Otero R, Maldonado-Garza HJ, Villarreal-Treviño L, Garza-González E. Current knowledge on the laboratory diagnosis of Clostridium difficile infection. World J Gastroenterol 2017; 23(9): 1552-1567 [PMID: 28321156 DOI: 10.3748/wjg.v23.i9.1552] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
28 Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis 2021;21:456. [PMID: 34016040 DOI: 10.1186/s12879-021-06147-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Aljafel NA, Al-Shaikhy HH, Alnahdi MA, Thabit AK. Incidence of Clostridioides difficile infection at a Saudi Tertiary Academic Medical Center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period. J Infect Public Health 2020;13:1156-60. [PMID: 32276872 DOI: 10.1016/j.jiph.2020.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Daniel A, Rapose A. The evaluation of Clostridium difficile infection (CDI) in a community hospital. J Infect Public Health 2015;8:155-60. [PMID: 25301221 DOI: 10.1016/j.jiph.2014.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
31 Schulz-Stübner S, Textor Z, Anetseder M. Fecal Microbiota Therapy as Rescue Therapy for Life-Threatening Clostridium difficile Infection in the Critically Ill: A Small Case Series. Infect Control Hosp Epidemiol 2016;37:1129-31. [PMID: 27452730 DOI: 10.1017/ice.2016.158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Marín M, Martín A, Alcalá L, Cercenado E, Iglesias C, Reigadas E, Bouza E. Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfr. Antimicrob Agents Chemother 2015;59:586-9. [PMID: 25385106 DOI: 10.1128/AAC.04082-14] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
33 Sartelli M, Pagani L, Iannazzo S, Moro ML, Viale P, Pan A, Ansaloni L, Coccolini F, D'Errico MM, Agreiter I, Amadio Nespola G, Barchiesi F, Benigni V, Binazzi R, Cappanera S, Chiodera A, Cola V, Corsi D, Cortese F, Crapis M, Cristini F, D'Arpino A, De Simone B, Di Bella S, Di Marzo F, Donati A, Elisei D, Fantoni M, Ferrari A, Foghetti D, Francisci D, Gattuso G, Giacometti A, Gesuelli GC, Marmorale C, Martini E, Meledandri M, Murri R, Padrini D, Palmieri D, Pauri P, Rebagliati C, Ricchizzi E, Sambri V, Schimizzi AM, Siquini W, Scoccia L, Scoppettuolo G, Sganga G, Storti N, Tavio M, Toccafondi G, Tumietto F, Viaggi B, Vivarelli M, Tranà C, Raso M, Labricciosa FM, Dhingra S, Catena F. A proposal for a comprehensive approach to infections across the surgical pathway. World J Emerg Surg 2020;15:13. [PMID: 32070390 DOI: 10.1186/s13017-020-00295-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
34 Rosignoli C, Petruzzellis G, Radici V, Facchin G, Girgenti M, Stella R, Isola M, Battista M, Sperotto A, Geromin A, Cerno M, Arzese A, Deias P, Tascini C, Fanin R, Patriarca F. Risk Factors and Outcome of C. difficile Infection after Hematopoietic Stem Cell Transplantation. J Clin Med 2020;9:E3673. [PMID: 33207616 DOI: 10.3390/jcm9113673] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Chia JH, Feng Y, Su LH, Wu TL, Chen CL, Liang YH, Chiu CH. Clostridium innocuum is a significant vancomycin-resistant pathogen for extraintestinal clostridial infection. Clin Microbiol Infect 2017;23:560-6. [PMID: 28254687 DOI: 10.1016/j.cmi.2017.02.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
36 Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. Int J Antimicrob Agents 2015;46:205-8. [PMID: 26055927 DOI: 10.1016/j.ijantimicag.2015.03.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
37 Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. Am J Health Syst Pharm 2019;76:581-90. [PMID: 31361830 DOI: 10.1093/ajhp/zxz032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
38 Bhattacharyya M, Debnath AK, Todi SK. Clostridium difficile and Antibiotic-associated Diarrhea. Indian J Crit Care Med 2020;24:S162-7. [PMID: 33354035 DOI: 10.5005/jp-journals-10071-23619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Lagier J, Raoult D. Greffe de microbiote fécal et infections: Mise au point, perspectives. Med Sci (Paris) 2016;32:991-7. [DOI: 10.1051/medsci/20163211015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
40 Cornely O, Cuenca-estrella M, Meis J, Ullmann A. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clinical Microbiology and Infection 2014;20:1-4. [DOI: 10.1111/1469-0691.12569] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
41 Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Mortality Among a National Cohort of Veterans With Recurrent Clostridium difficile Infection. Open Forum Infect Dis 2018;5:ofy175. [PMID: 30327788 DOI: 10.1093/ofid/ofy175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
42 Karyal C, Hughes J, Kelly ML, Luckett JC, Kaye PV, Cockayne A, Minton NP, Griffin R. Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. Microorganisms 2021;9:306. [PMID: 33540694 DOI: 10.3390/microorganisms9020306] [Reference Citation Analysis]
43 Cortés P, Bi Y, Stancampiano F, Valery JR, Cooper JH, Harris DM. Clostridioides Difficile Infection: A comprehensive review for primary providers. Rom J Intern Med 2021. [PMID: 33713592 DOI: 10.2478/rjim-2021-0010] [Reference Citation Analysis]
44 Jingjing S, Yanshu Z, Yu L, Qindong S, Xue W, Lei Z, Yingli H, Litao G. Factors related to antibiotic-associated diarrhea in patients in the intensive care unit receiving antifungals: a single-center retrospective study. J Int Med Res 2019;47:2067-76. [PMID: 30898003 DOI: 10.1177/0300060519836305] [Reference Citation Analysis]
45 Chen Y, Rashid MU, Huang H, Fang H, Nord CE, Wang M, Weintraub A. Molecular characteristics of Clostridium difficile strains from patients with a first recurrence more than 8 weeks after the primary infection. J Microbiol Immunol Infect 2017;50:532-6. [PMID: 26698688 DOI: 10.1016/j.jmii.2015.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother 2015;70:1751-6. [PMID: 25652750 DOI: 10.1093/jac/dkv006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
47 Markovic S, Jankovic M, Kalaba A, Zogovic B, Sreckovic SS. Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series. Cureus 2021;13:e19019. [PMID: 34824934 DOI: 10.7759/cureus.19019] [Reference Citation Analysis]
48 Leeds JA. Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571. Cold Spring Harb Perspect Med 2016;6:a025445. [PMID: 26834162 DOI: 10.1101/cshperspect.a025445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
49 Verbeke F, Janssens Y, Wynendaele E, De Spiegeleer B. Faecal microbiota transplantation: a regulatory hurdle? BMC Gastroenterol 2017;17:128. [PMID: 29179687 DOI: 10.1186/s12876-017-0687-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
50 Péju E, Arcizet J, Fillion A, Chavanet P, Prudent C, Piroth L. Multiple Recurrences of Clostridium difficile Infection Treated With Crushed Fidaxomicin Administered Through a Percutaneous Endoscopic Gastrostomy Tube. Ann Pharmacother 2015;49:853-4. [PMID: 26089544 DOI: 10.1177/1060028015581010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Bibbò S, Settanni CR, Porcari S, Bocchino E, Ianiro G, Cammarota G, Gasbarrini A. Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. J Clin Med 2020;9:E1757. [PMID: 32517023 DOI: 10.3390/jcm9061757] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
52 Chen YB, Gu SL, Shen P, Lv T, Fang YH, Tang LL, Li LJ. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China. J Med Microbiol 2018;67:52-9. [PMID: 29160203 DOI: 10.1099/jmm.0.000646] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
53 Fisher A, Khanal P, Gniado E, Khaddour L, Orosey M, Hader I, Yadav S, Halalau A. A Retrospective Study Analyzing the Appropriateness of Initial Treatment of Clostridium difficile in Patients with Active Malignancy. Gastroenterol Res Pract 2018;2018:7192728. [PMID: 29991944 DOI: 10.1155/2018/7192728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 2016;29:147-54. [PMID: 27065726 DOI: 10.20524/aog.2016.0006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
55 Averbuch D. Bacterial Infections. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 265-72. [DOI: 10.1007/978-3-030-02278-5_36] [Reference Citation Analysis]
56 Jarrad AM, Blaskovich MAT, Lyras D, Cooper MA. Clostridium difficile Infection: Current and Emerging Therapeutics. Curr Treat Options Infect Dis 2015;7:317-34. [DOI: 10.1007/s40506-015-0062-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Ramsay I, Brown NM, Enoch DA. Recent Progress for the Effective Prevention and Treatment of Recurrent Clostridium difficile Infection. Infect Dis (Auckl) 2018;11:1178633718758023. [PMID: 29535530 DOI: 10.1177/1178633718758023] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
58 Wenzler E, Mulugeta SG, Danziger LH. The Antimicrobial Stewardship Approach to Combating Clostridium Difficile. Antibiotics (Basel) 2015;4:198-215. [PMID: 27025621 DOI: 10.3390/antibiotics4020198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
59 Kurti Z, Lovasz BD, Mandel MD, Csima Z, Golovics PA, Csako BD, Mohas A, Gönczi L, Gecse KB, Kiss LS, Szathmari M, Lakatos PL. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol 2015; 21(21): 6728-6735 [PMID: 26074711 DOI: 10.3748/wjg.v21.i21.6728] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
60 Wang D, Dong D, Wang C, Cui Y, Jiang C, Ni Q, Su T, Wang G, Mao E, Peng Y. Risk factors and intestinal microbiota: Clostridioides difficile infection in patients receiving enteral nutrition at Intensive Care Units. Crit Care 2020;24:426. [PMID: 32660525 DOI: 10.1186/s13054-020-03119-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Mergenhagen KA, Wojciechowski AL, Paladino JA. A Review of the Economics of Treating Clostridium difficile Infection. PharmacoEconomics 2014;32:639-50. [DOI: 10.1007/s40273-014-0161-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
62 Batista R, Kapel N, Megerlin F, Chaumeil J, Barbut F, Bourlioux P, Chast F. Le transfert de microbiote fécal lors d’infections récidivantes à Clostridium difficile. Cadre et aspects pharmacotechniques. Annales Pharmaceutiques Françaises 2015;73:323-31. [DOI: 10.1016/j.pharma.2015.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
63 Bader MS, Hawboldt J, Main C, Mertz D, Loeb M, Farrell A, Joyce J. Review of high dose vancomycin in the treatment of Clostridioides difficile infection. Infect Dis (Lond) 2020;52:847-57. [PMID: 32744879 DOI: 10.1080/23744235.2020.1800080] [Reference Citation Analysis]
64 Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: current clinical efficacy and future prospects. Clin Exp Gastroenterol. 2015;8:285-291. [PMID: 26566371 DOI: 10.2147/ceg.s61305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
65 Littmann ER, Lee JJ, Denny JE, Alam Z, Maslanka JR, Zarin I, Matsuda R, Carter RA, Susac B, Saffern MS, Fett B, Mattei LM, Bittinger K, Abt MC. Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection. Nat Commun 2021;12:755. [PMID: 33531483 DOI: 10.1038/s41467-020-20793-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
66 Lagier JC. Faecal microbiota transplantation: from practice to legislation before considering industrialization. Clin Microbiol Infect 2014;20:1112-8. [PMID: 25273480 DOI: 10.1111/1469-0691.12795] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
67 San-Juan R, Fernández-Ruiz M, Ruiz-Ruigómez M, López-Medrano F, Ruiz-Merlo T, Andrés A, Loinaz C, Len O, Azancot MA, Montejo M, Rodriguez-Alvarez R, Fortún J, Escudero-Sánchez R, Giménez E, Lora D, Albert E, Navarro D, Aguado JM; Spanish Network for Research in Infectious Diseases (Red Española de Investigación en Patología Infecciosa [REIPI] RD16/0016). A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score. J Infect Dis 2020;222:479-87. [PMID: 32112085 DOI: 10.1093/infdis/jiaa090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Leal J, Ronksley P, Henderson EA, Conly J, Manns B. Predictors of mortality and length of stay in patients with hospital-acquired Clostridioides difficile infection: a population-based study in Alberta, Canada. J Hosp Infect 2019;103:85-91. [PMID: 30991081 DOI: 10.1016/j.jhin.2019.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
69 Korayem GB, Eljaaly K, Matthias KR, Zangeneh TT. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study. Transplant Proc 2018;50:137-41. [PMID: 29407296 DOI: 10.1016/j.transproceed.2017.11.016] [Reference Citation Analysis]
70 Burz SD, Abraham AL, Fonseca F, David O, Chapron A, Béguet-Crespel F, Cénard S, Le Roux K, Patrascu O, Levenez F, Schwintner C, Blottière HM, Béra-Maillet C, Lepage P, Doré J, Juste C. A Guide for Ex Vivo Handling and Storage of Stool Samples Intended for Fecal Microbiota Transplantation. Sci Rep 2019;9:8897. [PMID: 31222022 DOI: 10.1038/s41598-019-45173-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
71 Hvas CL, Dahl Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L, Hansen MM, Erikstrup C, Dahlerup JF. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology 2019;156:1324-1332.e3. [DOI: 10.1053/j.gastro.2018.12.019] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 33.0] [Reference Citation Analysis]
72 Neuendorf M, Guadarrama-Gonzalez R, Lamik B, MacKenzie CR. A prospective study of two isothermal amplification assays compared with real-time PCR, CCNA and toxigenic culture for the diagnosis of Clostridium difficile infection. BMC Microbiol. 2016;16:19. [PMID: 26868647 DOI: 10.1186/s12866-016-0635-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
73 Steindl G, Fiedler A, Huhulescu S, Wewalka G, Allerberger F. Effect of airborne hydrogen peroxide on spores of Clostridium difficile. Wien Klin Wochenschr 2015;127:421-6. [PMID: 25527140 DOI: 10.1007/s00508-014-0682-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
74 Quigley L, Coakley M, Alemayehu D, Rea MC, Casey PG, O'Sullivan Ó, Murphy E, Kiely B, Cotter PD, Hill C, Ross RP. Lactobacillus gasseri APC 678 Reduces Shedding of the Pathogen Clostridium difficile in a Murine Model. Front Microbiol 2019;10:273. [PMID: 30842760 DOI: 10.3389/fmicb.2019.00273] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
75 Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents 2016;48:137-43. [PMID: 27283730 DOI: 10.1016/j.ijantimicag.2016.04.026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
76 Shin JH, Chaves-Olarte E, Warren CA. Clostridium difficile Infection. Microbiol Spectr 2016;4. [PMID: 27337475 DOI: 10.1128/microbiolspec.EI10-0007-2015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
77 Kump PK, Krause R, Allerberger F, Högenauer C. Faecal microbiota transplantation--the Austrian approach. Clin Microbiol Infect 2014;20:1106-11. [PMID: 25274251 DOI: 10.1111/1469-0691.12801] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
78 Cassir N, Fahsi N, Durand G, Lagier JC, Raoult D, Fournier PE. Emergence of Clostridium difficile tcdC variant 078 in Marseille, France. Eur J Clin Microbiol Infect Dis 2017;36:1971-4. [PMID: 28573471 DOI: 10.1007/s10096-017-3022-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
79 Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Gerhard M, Thoeringer CK, Vehreschild MJGT, Jazmati N, Rupp J, Manns MP, Bachmann O, Suerbaum S. BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection. PLoS One 2018;13:e0196977. [PMID: 29738579 DOI: 10.1371/journal.pone.0196977] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
80 Kuijper EJ, Allegretii J, Hawkey P, Sokol H, Goldenberg S, Ianiro G, Gasbarrini A, Kump P, Costello SP, Keller J, Vehreschild MJGT. A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. Lancet Infect Dis 2019;19:1161-2. [PMID: 31657769 DOI: 10.1016/S1473-3099(19)30545-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
81 Sokol H, Lalande V, Landman C, Bourrier A, Nion-Larmurier I, Rajca S, Kirchgesner J, Seksik P, Cosnes J, Barbut F, Beaugerie L. Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study. Dig Liver Dis 2017;49:643-6. [PMID: 28215602 DOI: 10.1016/j.dld.2017.01.162] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
82 Piper MS, Saad RJ. Diabetes Mellitus and the Colon. Curr Treat Options Gastroenterol. 2017;15:460-474. [PMID: 29063998 DOI: 10.1007/s11938-017-0151-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
83 Amrane S, Hocquart M, Afouda P, Kuete E, Pham TP, Dione N, Ngom II, Valles C, Bachar D, Raoult D, Lagier JC. Metagenomic and culturomic analysis of gut microbiota dysbiosis during Clostridium difficile infection. Sci Rep 2019;9:12807. [PMID: 31488869 DOI: 10.1038/s41598-019-49189-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
84 Malamood M, Nellis E, Ehrlich AC, Friedenberg FK. Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection. J Clin Med Res 2015;7:422-7. [PMID: 25883704 DOI: 10.14740/jocmr2117w] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
85 Liu D, Zeng L, Yan Z, Jia J, Gao J, Wei Y. The mechanisms and safety of probiotics against toxigenic clostridium difficile. Expert Rev Anti Infect Ther 2020;18:967-75. [PMID: 32520637 DOI: 10.1080/14787210.2020.1778464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Nyc O, Krutova M, Liskova A, Matejkova J, Drabek J, Kuijper EJ. The emergence of Clostridium difficile PCR-ribotype 001 in Slovakia. Eur J Clin Microbiol Infect Dis 2015;34:1701-8. [DOI: 10.1007/s10096-015-2407-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
87 Hong S, Knight DR, Riley TV. The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection. Microbiol Aust 2019;40:77. [DOI: 10.1071/ma19022] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Howerton A, Seymour CO, Murugapiran SK, Liao Z, Phan JR, Estrada A, Wagner AJ, Mefferd CC, Hedlund BP, Abel-Santos E. Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection. Antimicrob Agents Chemother 2018;62:e02251-17. [PMID: 30012758 DOI: 10.1128/AAC.02251-17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
89 Lagier JC, Delord M, Million M, Parola P, Stein A, Brouqui P, Raoult D. Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report. Eur J Clin Microbiol Infect Dis 2015;34:1597-601. [PMID: 25947205 DOI: 10.1007/s10096-015-2394-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
90 Lam SW, Neuner EA, Fraser TG, Delgado D, Chalfin DB. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting. Infect Control Hosp Epidemiol 2018;39:924-30. [PMID: 29961435 DOI: 10.1017/ice.2018.139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
91 Waltz P, Zuckerbraun B. Novel therapies for severe Clostridium difficile colitis. Curr Opin Crit Care 2016;22:167-73. [PMID: 26771898 DOI: 10.1097/MCC.0000000000000282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
92 Sadowska-Klasa A, Piekarska A, Prejzner W, Bieniaszewska M, Hellmann A. Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation. Ann Hematol 2018;97:509-17. [PMID: 29255911 DOI: 10.1007/s00277-017-3205-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
93 Serafino S, Consonni D, Migone De Amicis M, Sisto F, Domeniconi G, Formica S, Zarantonello M, Maraschini A, Cappellini MD, Spigaglia P, Barbanti F, Castaldi S, Fabio G. Clinical outcomes of Clostridium difficile infection according to strain type. A prospective study in medical wards. Eur J Intern Med 2018;54:21-6. [PMID: 29650357 DOI: 10.1016/j.ejim.2018.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
94 Galpérine T, Guery B; French Group of Fecal Microbiota Transplantation (GFTF). Exploring ways to improve CDI outcomes. Med Mal Infect 2018;48:10-7. [PMID: 29336930 DOI: 10.1016/j.medmal.2017.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Lankelma JM, van Vught LA, Belzer C, Schultz MJ, van der Poll T, de Vos WM, Wiersinga WJ. Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study. Intensive Care Med. 2017;43:59-68. [PMID: 27837233 DOI: 10.1007/s00134-016-4613-z] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 15.5] [Reference Citation Analysis]
96 Psoinos CM, Collins CE, Ayturk MD, Anderson FA, Santry HP. Post-hospitalization Treatment Regimen and Readmission for C. difficile Colitis in Medicare Beneficiaries. World J Surg 2018;42:246-53. [PMID: 28744593 DOI: 10.1007/s00268-017-4139-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
97 Karlowsky JA, Adam HJ, Baxter MR, Dutka CW, Nichol KA, Laing NM, Golding GR, Zhanel GG. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017. Journal of Antimicrobial Chemotherapy 2020;75:1824-32. [DOI: 10.1093/jac/dkaa118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
98 Keller JJ, Vehreschild MJ, Hvas CL, Jørgensen SM, Kupciskas J, Link A, Mulder CJ, Goldenberg SD, Arasaradnam R, Sokol H, Gasbarrini A, Hoegenauer C, Terveer EM, Kuijper EJ, Arkkila P; UEG working group of the Standards and Guidelines initiative Stool banking for FMT. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterol J 2019;7:1408-10. [PMID: 31839966 DOI: 10.1177/2050640619887579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
99 Šamadan L, Jeličić M, Vince A, Papić N. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:780. [PMID: 34198964 DOI: 10.3390/antibiotics10070780] [Reference Citation Analysis]
100 Durovic A, Widmer AF, Frei R, Tschudin-Sutter S. Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations. Infect Control Hosp Epidemiol 2017;38:891-6. [PMID: 28592348 DOI: 10.1017/ice.2017.119] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
101 Dinh A, Bouchand F, Le Monnier A. Actualités épidémiologiques et thérapeutiques des infections à Clostridium difficile. La Revue de Médecine Interne 2015;36:596-602. [DOI: 10.1016/j.revmed.2015.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
102 Kachrimanidou M, Sarmourli T, Skoura L, Metallidis S, Malisiovas N. Clostridium difficile infection: New insights into therapeutic options. Crit Rev Microbiol 2016;42:773-9. [PMID: 25955884 DOI: 10.3109/1040841X.2015.1027171] [Reference Citation Analysis]
103 Malard F, Dore J, Gaugler B, Mohty M. Introduction to host microbiome symbiosis in health and disease. Mucosal Immunol 2021;14:547-54. [PMID: 33299088 DOI: 10.1038/s41385-020-00365-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
104 Ding NS, Mullish BH, McLaughlin J, Hart A, Marchesi JR. Meeting update: faecal microbiota transplantation--bench, bedside, courtroom? Frontline Gastroenterol 2018;9:45-8. [PMID: 29484160 DOI: 10.1136/flgastro-2016-100752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
105 Polivkova S, Krutova M, Petrlova K, Benes J, Nyc O. Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread? Anaerobe 2016;40:35-40. [PMID: 27155489 DOI: 10.1016/j.anaerobe.2016.05.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
106 Wurm P, Spindelboeck W, Krause R, Plank J, Fuchs G, Bashir M, Petritsch W, Halwachs B, Langner C, Högenauer C, Gorkiewicz G. Antibiotic-Associated Apoptotic Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion. Crit Care Med 2017;45:e600-6. [PMID: 28333760 DOI: 10.1097/CCM.0000000000002310] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
107 Kodadek LM, Lipsett PA. Prevention and Treatment of Clostridium difficile Enterocolitis. Adv Surg 2018;52:29-42. [PMID: 30098619 DOI: 10.1016/j.yasu.2018.04.001] [Reference Citation Analysis]
108 Ong GK, Reidy TJ, Huk MD, Lane FR. Clostridium difficile colitis: A clinical review. Am J Surg 2017;213:565-71. [PMID: 28131326 DOI: 10.1016/j.amjsurg.2016.10.035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
109 Cammarota G, Gallo A, Ianiro G, Montalto M. Emerging drugs for the treatment of clostridium difficile. Expert Opin Emerg Drugs 2019;24:17-28. [PMID: 30841760 DOI: 10.1080/14728214.2019.1591371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
110 Barbut F, Guery B, Eckert C. Comment traiter une infection digestive à Clostridium difficile en 2014 ? Réanimation 2014;23:284-97. [DOI: 10.1007/s13546-014-0867-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
112 Rodrigues R, Barber GE, Ananthakrishnan AN. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol 2017;38:196-202. [PMID: 27817758 DOI: 10.1017/ice.2016.246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
113 Sommermeyer H, Pituch HM, Wultanska D, Wojtyla-Buciora P, Piatek J, Bernatek M. Inhibition of Quinolone- and Multi-Drug-Resistant Clostridioides Difficile Strains by Multi Strain Synbiotics-An Option for Diarrhea Management in Nursing Facilities. Int J Environ Res Public Health 2021;18:5871. [PMID: 34070727 DOI: 10.3390/ijerph18115871] [Reference Citation Analysis]
114 Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2018;97:31-49. [PMID: 29177551 DOI: 10.1007/s00277-017-3183-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
115 Martínez-meléndez A, Tijerina-rodríguez L, Morfin-otero R, Camacho-ortíz A, Villarreal-treviño L, Sánchez-alanís H, Rodríguez-noriega E, Baines SD, Flores-treviño S, Maldonado-garza HJ, Garza-gonzález E. Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico. Microbial Drug Resistance 2018;24:386-92. [DOI: 10.1089/mdr.2017.0323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
116 van Kleef E, Green N, Goldenberg S, Robotham J, Cookson B, Jit M, Edmunds W, Deeny S. Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach. Journal of Hospital Infection 2014;88:213-7. [DOI: 10.1016/j.jhin.2014.08.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
117 Panjad P, Yongsawas R, Sinpoo C, Pakwan C, Subta P, Krongdang S, In-On A, Chomdej S, Chantawannakul P, Disayathanoowat T. Impact of Nosema Disease and American Foulbrood on Gut Bacterial Communities of Honeybees Apis mellifera. Insects 2021;12:525. [PMID: 34204079 DOI: 10.3390/insects12060525] [Reference Citation Analysis]
118 Ford DC, Schroeder MC, Ince D, Ernst EJ. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients. American Journal of Health-System Pharmacy 2018;75:1110-21. [DOI: 10.2146/ajhp170554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
119 Postma N, Kiers D, Pickkers P. The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options. International Journal of Antimicrobial Agents 2015;46:S47-50. [DOI: 10.1016/j.ijantimicag.2015.11.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
120 Mamoon L, Olesen SW. Fecal Microbiota Transplants Annually and Their Positive Clinical Impact. Clin Transl Gastroenterol 2020;11:e00247. [PMID: 33259159 DOI: 10.14309/ctg.0000000000000247] [Reference Citation Analysis]
121 Kachrimanidou M, Tsachouridou O, Ziogas IA, Christaki E, Protonotariou E, Metallidis S, Skoura L, Kuijper E. Clostridium difficile infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126. J Med Microbiol 2017;66:1774-81. [PMID: 29087273 DOI: 10.1099/jmm.0.000623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
122 Murphy MM, Patatanian E, Gales MA. Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review. Ther Adv Infect Dis 2018;5:111-9. [PMID: 30430009 DOI: 10.1177/2049936118798276] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
123 Yang Z, Huang Q, Qin J, Zhang X, Jian Y, Lv H, Liu Q, Li M. Molecular Epidemiology and Risk Factors of Clostridium difficile ST81 Infection in a Teaching Hospital in Eastern China. Front Cell Infect Microbiol 2020;10:578098. [PMID: 33425775 DOI: 10.3389/fcimb.2020.578098] [Reference Citation Analysis]
124 Andrés-Lasheras S, Martín-Burriel I, Mainar-Jaime RC, Morales M, Kuijper E, Blanco JL, Chirino-Trejo M, Bolea R. Preliminary studies on isolates of Clostridium difficile from dogs and exotic pets. BMC Vet Res 2018;14:77. [PMID: 29523201 DOI: 10.1186/s12917-018-1402-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
125 Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis 2017;17:735-44. [PMID: 28461207 DOI: 10.1016/S1473-3099(17)30235-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 11.8] [Reference Citation Analysis]
126 Villafuerte Gálvez JA, Kelly CP. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection. Expert Review of Gastroenterology & Hepatology 2017;11:611-22. [DOI: 10.1080/17474124.2017.1344551] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
127 Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, Guery B, Dervaux B. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PLoS One 2017;12:e0170258. [PMID: 28103289 DOI: 10.1371/journal.pone.0170258] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
128 Moore JH 2nd, van Opstal E, Kolling GL, Shin JH, Bogatcheva E, Nikonenko B, Einck L, Phipps AJ, Guerrant RL, Protopopova M, Warren CA. Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model. J Antimicrob Chemother 2016;71:1300-6. [PMID: 26832756 DOI: 10.1093/jac/dkv479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
129 Krutova M, Nyc O, Matejkova J, Allerberger F, Wilcox MH, Kuijper EJ. Molecular characterisation of Czech Clostridium difficile isolates collected in 2013-2015. Int J Med Microbiol 2016;306:479-85. [PMID: 27519407 DOI: 10.1016/j.ijmm.2016.07.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
130 Barbanti F, Spigaglia P. Microbiological characteristics of human and animal isolates of Clostridioides difficile in Italy: Results of the Istituto Superiore di Sanità in the years 2006-2016. Anaerobe 2020;61:102136. [PMID: 31857201 DOI: 10.1016/j.anaerobe.2019.102136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Prior A, Kevans D, Mcdowell L, Cudmore S, Fitzpatrick F. Treatment of Clostridium difficile infection: a national survey of clinician recommendations and the use of faecal microbiota transplantation. Journal of Hospital Infection 2017;95:438-41. [DOI: 10.1016/j.jhin.2016.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
132 Okumura H, Fukushima A, Taieb V, Shoji S, English M. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis. J Infect Chemother 2020;26:43-50. [PMID: 31624029 DOI: 10.1016/j.jiac.2019.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
133 Guery B, Barbut F, Tschudin-Sutter S. Diagnostic and therapy of severe Clostridioides difficile infections in the ICU. Curr Opin Crit Care 2020;26:450-8. [PMID: 32739967 DOI: 10.1097/MCC.0000000000000753] [Reference Citation Analysis]
134 Nale JY, Redgwell TA, Millard A, Clokie MRJ. Efficacy of an Optimised Bacteriophage Cocktail to Clear Clostridium difficile in a Batch Fermentation Model. Antibiotics (Basel) 2018;7:E13. [PMID: 29438355 DOI: 10.3390/antibiotics7010013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
135 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Reference Citation Analysis]
136 Popovic N, Korac M, Nesic Z, Milosevic B, Urosevic A, Jevtovic D, Mitrovic N, Markovic A, Jordovic J, Katanic N, Barac A, Milosevic I. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study. Eur J Clin Microbiol Infect Dis 2018;37:745-54. [DOI: 10.1007/s10096-017-3169-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
137 Manthey C, Eckmann L, Fuhrmann V. Therapy for Clostridium difficile infection – any news beyond Metronidazole and Vancomycin? Expert Review of Clinical Pharmacology 2017;10:1239-50. [DOI: 10.1080/17512433.2017.1362978] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
138 Azimirad M, Yadegar A, Gholami F, Shahrokh S, Asadzadeh Aghdaei H, Ianiro G, Suzuki H, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. J Inflamm Res 2020;13:563-70. [PMID: 32982371 DOI: 10.2147/JIR.S265520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Larrainzar-Coghen T, Rodríguez-Pardo D, Fernández-Hidalgo N, Puig-Asensio M, Pigrau C, Ferrer C, Rodríguez V, Bartolomé R, Campany D, Almirante B. Secular trends in the epidemiology of Clostridium difficile infection (CDI) at a tertiary care hospital in Barcelona, 2006-2015: A prospective observational study. Anaerobe 2018;51:54-60. [PMID: 29655966 DOI: 10.1016/j.anaerobe.2018.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Doufair M, Eckert C, Drieux L, Amani-Moibeni C, Bodin L, Denis M, Grange JD, Arlet G, Barbut F. Clostridium difficile bacteremia: Report of two cases in French hospitals and comprehensive review of the literature. IDCases 2017;8:54-62. [PMID: 28417069 DOI: 10.1016/j.idcr.2017.03.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
141 Paknikar R, Pekow J. Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. Surg Infect (Larchmt). 2018;19:785-791. [PMID: 30300561 DOI: 10.1089/sur.2018.221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
142 Granata G, Petrosillo N, Adamoli L, Bartoletti M, Bartoloni A, Basile G, Bassetti M, Bonfanti P, Borromeo R, Ceccarelli G, De Luca AM, Di Bella S, Fossati S, Franceschini E, Gentile I, Giacobbe DR, Giacometti E, Ingrassia F, Lagi F, Lobreglio G, Lombardi A, Lupo LI, Luzzati R, Maraolo AE, Mikulska M, Mondelli MU, Mularoni A, Mussini C, Oliva A, Pandolfo A, Rogati C, Trapani FF, Venditti M, Viale P, Caraffa E, Cataldo MA, On Behalf Of The ReCloDi Recurrence Of Clostridioides Difficile Infection Study Group. Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. J Clin Med 2021;10:1127. [PMID: 33800334 DOI: 10.3390/jcm10051127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Hannet I, Engsbro AL, Pareja J, Schneider UV, Lisby JG, Pružinec-popović B, Hoerauf A, Parčina M. Multicenter evaluation of the new QIAstat Gastrointestinal Panel for the rapid syndromic testing of acute gastroenteritis. Eur J Clin Microbiol Infect Dis 2019;38:2103-12. [DOI: 10.1007/s10096-019-03646-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
144 Kang CY, Huang IH, Chou CC, Wu TY, Chang JC, Hsiao YY, Cheng CH, Tsai WJ, Hsu KC, Wang S. Functional analysis of Clostridium difficile sortase B reveals key residues for catalytic activity and substrate specificity. J Biol Chem 2020;295:3734-45. [PMID: 32005667 DOI: 10.1074/jbc.RA119.011322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
145 Keller JJ, Ooijevaar RE, Hvas CL, Terveer EM, Lieberknecht SC, Högenauer C, Arkkila P, Sokol H, Gridnyev O, Mégraud F, Kump PK, Nakov R, Goldenberg SD, Satokari R, Tkatch S, Sanguinetti M, Cammarota G, Dorofeev A, Gubska O, Laniro G, Mattila E, Arasaradnam RP, Sarin SK, Sood A, Putignani L, Alric L, Baunwall SMD, Kupcinskas J, Link A, Goorhuis AG, Verspaget HW, Ponsioen C, Hold GL, Tilg H, Kassam Z, Kuijper EJ, Gasbarrini A, Mulder CJJ, Williams HRT, Vehreschild MJGT. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterol J 2021;9:229-47. [PMID: 33151137 DOI: 10.1177/2050640620967898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
146 Matijašić M, Meštrović T, Perić M, Čipčić Paljetak H, Panek M, Vranešić Bender D, Ljubas Kelečić D, Krznarić Ž, Verbanac D. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. Int J Mol Sci 2016;17:E578. [PMID: 27104515 DOI: 10.3390/ijms17040578] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
147 Carmo J, Marques S, Chapim I, Túlio MA, Rodrigues JP, Bispo M, Chagas C. Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015. GE Port J Gastroenterol 2015;22:259-67. [PMID: 28868417 DOI: 10.1016/j.jpge.2015.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
148 Pareja-sierra T. Diarrea asociada a Clostridium difficile en el anciano: nuevas perspectivas. Revista Española de Geriatría y Gerontología 2014;49:188-93. [DOI: 10.1016/j.regg.2014.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res 2021;19:265-74. [PMID: 32806873 DOI: 10.5217/ir.2020.00045] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Bruxelle JF, Mizrahi A, Hoÿs S, Collignon A, Janoir C, Péchiné S. Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile. PLoS One 2017;12:e0187212. [PMID: 29176760 DOI: 10.1371/journal.pone.0187212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
151 Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe 2015;34:59-73. [PMID: 25930686 DOI: 10.1016/j.anaerobe.2015.04.012] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 7.7] [Reference Citation Analysis]
152 Hocquart M, Lagier J, Cassir N, Saidani N, Eldin C, Kerbaj J, Delord M, Valles C, Brouqui P, Raoult D, Million M. Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections. Clinical Infectious Diseases 2018;66:645-50. [DOI: 10.1093/cid/cix762] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
153 Páramo-Zunzunegui J, Ortega-Fernández I, Calvo-Espino P, Diego-Hernández C, Ariza-Ibarra I, Otazu-Canals L, Danés-Grases JE, Menchero-Sánchez A. Severe Clostridium difficile colitis as potential late complication associated with COVID-19. Ann R Coll Surg Engl 2020;102:e176-9. [PMID: 32803988 DOI: 10.1308/rcsann.2020.0166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Breuer C, Döring S, Rohde H, Rutkowski S, Müller I, Oh J. Clostridium difficile infection after pediatric solid organ transplantation: a practical single-center experience. Pediatr Nephrol 2019;34:1269-75. [PMID: 30843115 DOI: 10.1007/s00467-019-04219-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Ianiro G, Bibbò S, Masucci L, Quaranta G, Porcari S, Settanni CR, Lopetuso LR, Fantoni M, Sanguinetti M, Gasbarrini A, Cammarota G. Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study. Dig Liver Dis 2020;52:1390-5. [PMID: 33004295 DOI: 10.1016/j.dld.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
156 Fadda HM. The Route to Palatable Fecal Microbiota Transplantation. AAPS PharmSciTech 2020;21:114. [PMID: 32296975 DOI: 10.1208/s12249-020-1637-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
157 Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of Medical Economics 2017;20:678-86. [DOI: 10.1080/13696998.2017.1302946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
158 Varkonyi I, Rakoczi E, Misak O, Komaromi E, Kardos L, Lampe Z, Szilvassy Z. Findings of a hospital surveillance-based outcome evaluation study for Clostridium difficile-associated colitis. Clinical Microbiology and Infection 2014;20:1085-90. [DOI: 10.1111/1469-0691.12652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
159 Penit A, Bemer P, Besson J, Cazet L, Bourigault C, Juvin ME, Fix MH, Bruley des Varannes S, Boutoille D, Batard E, Lepelletier D. Community-acquired Clostridium difficile infections. Med Mal Infect 2016;46:131-9. [PMID: 27039068 DOI: 10.1016/j.medmal.2016.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
160 Knight DR, Elliott B, Chang BJ, Perkins TT, Riley TV. Diversity and Evolution in the Genome of Clostridium difficile. Clin Microbiol Rev 2015;28:721-41. [PMID: 26085550 DOI: 10.1128/CMR.00127-14] [Cited by in Crossref: 146] [Cited by in F6Publishing: 84] [Article Influence: 20.9] [Reference Citation Analysis]
161 Cheminet G, Kapel N, Bleibtreu A, Sadou Yayé H, Bellanger A, Duval X, Joly F, Fantin B, de Lastours V. Faecal microbiota transplantation with frozen capsules for relapsing Clostridium difficile infections: the first experience from 15 consecutive patients in France. Journal of Hospital Infection 2018;100:148-51. [DOI: 10.1016/j.jhin.2018.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
162 König J, Siebenhaar A, Högenauer C, Arkkila P, Nieuwdorp M, Norén T, Ponsioen CY, Rosien U, Rossen NG, Satokari R, Stallmach A, de Vos W, Keller J, Brummer RJ. Consensus report: faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther 2017;45:222-39. [PMID: 27891639 DOI: 10.1111/apt.13868] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 12.0] [Reference Citation Analysis]
163 Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, Sanguinetti M, Gasbarrini A. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-843. [PMID: 25728808 DOI: 10.1111/apt.13144] [Cited by in Crossref: 331] [Cited by in F6Publishing: 297] [Article Influence: 47.3] [Reference Citation Analysis]
164 Vigvári S, Sipos D, Solt J, Vincze Á, Kocsis B, Nemes Z, Kappéter Á, Feiszt Z, Kovács B, Péterfi Z. Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients. Acta Microbiol Immunol Hung 2019;66:69-78. [PMID: 29239198 DOI: 10.1556/030.64.2017.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
165 Chiang HY, Huang HC, Chung CW, Yeh YC, Chen YC, Tien N, Lin HS, Ho MW, Kuo CC. Risk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study. Antimicrob Resist Infect Control 2019;8:175. [PMID: 31749963 DOI: 10.1186/s13756-019-0642-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
166 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Maxwell-Scott HG, Goldenberg SD. Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents. Med Mal Infect 2018;48:1-9. [PMID: 29169816 DOI: 10.1016/j.medmal.2017.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
168 Xu Q, Chen Y, Gu S, Lv T, Zheng B, Shen P, Quan J, Fang Y, Li L. Hospital-acquired Clostridium difficile infection in Mainland China: A seven-year (2009-2016) retrospective study in a large university hospital. Sci Rep 2017;7:9645. [PMID: 28852010 DOI: 10.1038/s41598-017-09961-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
169 Galdys AL, Curry SR, Harrison LH. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. Expert Review of Anti-infective Therapy 2014;12:967-80. [DOI: 10.1586/14787210.2014.920252] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
170 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Cheng JW, Yang QW, Xiao M, Yu SY, Zhou ML, Kudinha T, Kong F, Liao JW, Xu YC. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. J Microbiol Immunol Infect 2018;51:411-6. [PMID: 28693926 DOI: 10.1016/j.jmii.2017.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
172 Shin J, Wi YM, Lee YJ. Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea. Epidemiol Infect 2019;147:e289. [PMID: 31607272 DOI: 10.1017/S0950268819001742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
173 Aira A, Fehér C, Rubio E, Soriano A. The Intestinal Microbiota as a Reservoir and a Therapeutic Target to Fight Multi-Drug-Resistant Bacteria: A Narrative Review of the Literature. Infect Dis Ther 2019;8:469-82. [PMID: 31654298 DOI: 10.1007/s40121-019-00272-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
174 Chang TH, Hsu WY, Yang TI, Lu CY, Hsueh PR, Chen JM, Lee PI, Huang LM, Chang LY. Increased age and proton pump inhibitors are associated with severe Clostridium difficile infections in children. J Microbiol Immunol Infect 2020;53:578-84. [PMID: 30287184 DOI: 10.1016/j.jmii.2018.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
175 Shah DN, Chan FS, Kachru N, Garcia KP, Balcer HE, Dyer AP, Emanuel JE, Jordan MD, Lusardi KT, Naymick G, Polisetty RS, Sieman L, Tyler AM, Johnson ML, Garey KW. A multi-center study of fidaxomicin use for Clostridium difficile infection. Springerplus 2016;5:1224. [PMID: 27536508 DOI: 10.1186/s40064-016-2825-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
176 Baghani A, Ghourchian S, Aliramezani A, Yaseri M, Mesdaghinia A, Douraghi M. Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients. J Appl Microbiol 2018;125:1518-25. [PMID: 29957893 DOI: 10.1111/jam.14035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
177 Katzman M. Antibiotic therapy for Clostridium difficile infection. Seminars in Colon and Rectal Surgery 2014;25:143-9. [DOI: 10.1053/j.scrs.2014.05.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
178 Banawas SS. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. Biomed Res Int 2018;2018:8414257. [PMID: 29682562 DOI: 10.1155/2018/8414257] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
179 Gergely Szabo B, Kadar B, Szidonia Lenart K, Dezsenyi B, Kunovszki P, Fried K, Kamotsay K, Nikolova R, Prinz G. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clinical Microbiology and Infection 2016;22:990-5. [DOI: 10.1016/j.cmi.2016.08.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
180 Salavert M, Cobo J, Pascual Á, Aragón B, Maratia S, Jiang Y, Aceituno S, Grau S. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Adv Ther 2018;35:1920-34. [PMID: 30328061 DOI: 10.1007/s12325-018-0813-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
181 Moelling K, Broecker F. Fecal microbiota transplantation to fight Clostridium difficile infections and other intestinal diseases. Bacteriophage 2016;6:e1251380. [PMID: 28090385 DOI: 10.1080/21597081.2016.1251380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
182 Fountain EM, Moses MC, Park LP, Woods CW, Arepally GM. Thrombocytopenia in hospitalized patients with severe clostridium difficile infection. J Thromb Thrombolysis 2017;43:38-42. [PMID: 27614757 DOI: 10.1007/s11239-016-1423-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
183 Lefevre-tantet-etchebarne D, Sivadon-tardy V, Davido B, Bouchand F, Grenet J, Farfour E, Getti R, Duran C, Chéron M, Mathieu E, Salomon J, Dinh A. Community-acquired Clostridium difficile infections in emergency departments. Médecine et Maladies Infectieuses 2016;46:372-9. [DOI: 10.1016/j.medmal.2016.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
184 Peng Z, Jin D, Kim HB, Stratton CW, Wu B, Tang YW, Sun X. Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing. J Clin Microbiol 2017;55:1998-2008. [PMID: 28404671 DOI: 10.1128/JCM.02250-16] [Cited by in Crossref: 95] [Cited by in F6Publishing: 57] [Article Influence: 19.0] [Reference Citation Analysis]
185 Zhou FF, Wu S, Klena JD, Huang HH. Clinical characteristics of Clostridium difficile infection in hospitalized patients with antibiotic-associated diarrhea in a university hospital in China. Eur J Clin Microbiol Infect Dis 2014;33:1773-9. [PMID: 24820293 DOI: 10.1007/s10096-014-2132-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
186 Katzer KC, Hagel S, Reuken PA, Bruns T, Stallmach A. Development and validation of a simple and robust model to predict 30-day mortality in patients with Clostridioides difficile-associated enterocolitis. BMJ Open Gastroenterol 2020;7:e000468. [PMID: 32912845 DOI: 10.1136/bmjgast-2020-000468] [Reference Citation Analysis]
187 Cammarota G, Gallo A, Bibbò S. Fecal microbiota transplant for C. difficile infection: Just say yes. Anaerobe 2019;60:102109. [PMID: 31644957 DOI: 10.1016/j.anaerobe.2019.102109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
188 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
189 Wintenberger C, Guery B, Bonnet E, Castan B, Cohen R, Diamantis S, Lesprit P, Maulin L, Péan Y, Peju E, Piroth L, Stahl JP, Strady C, Varon E, Vuotto F, Gauzit R; Recommendation Group of the SPILF. Proposal for shorter antibiotic therapies. Med Mal Infect 2017;47:92-141. [PMID: 28279491 DOI: 10.1016/j.medmal.2017.01.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 6.6] [Reference Citation Analysis]
190 Muñoz P, Valerio M, Vásquez V, Velásquez-Rodríguez J, Sousa I, Zatarain E, Barrio JM, Ruiz M, Cuerpo G, Rodríguez-Abella H, Hortal J, Bouza E; “Grupo de Apoyo al Manejo de las Asistencias Ventriculares” (GAMAV). Infections in patients after Berlin Heart® EXCOR assist device implantation. Transpl Infect Dis 2018;20:e12936. [PMID: 29846991 DOI: 10.1111/tid.12936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Wilcox MH, Cornely OA, Guery B, Longshaw C, Georgopali A, Karas A, Kazeem G, Palacios-Fabrega JA, Vehreschild MJGT. Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study. Open Forum Infect Dis 2019;6:ofz436. [PMID: 31723569 DOI: 10.1093/ofid/ofz436] [Reference Citation Analysis]
192 Oleastro M, Coelho M, Gião M, Coutinho S, Mota S, Santos A, Rodrigues J, Faria D. Outbreak of Clostridium difficile PCR ribotype 027--the recent experience of a regional hospital. BMC Infect Dis 2014;14:209. [PMID: 24739945 DOI: 10.1186/1471-2334-14-209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
193 Peng Z, Wang S, Gide M, Zhu D, Lamabadu Warnakulasuriya Patabendige HM, Li C, Cai J, Sun X. A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Clostridioides difficile Infection in Mice. Front Microbiol 2018;9:3234. [PMID: 30687250 DOI: 10.3389/fmicb.2018.03234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
194 White NC, Mendo-Lopez R, Papamichael K, Cuddemi CA, Barrett C, Daugherty K, Pollock N, Kelly CP, Alonso CD. Laxative Use Does Not Preclude Diagnosis or Reduce Disease Severity in Clostridiodes difficile Infection. Clin Infect Dis 2020;71:1472-8. [PMID: 31584632 DOI: 10.1093/cid/ciz978] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
195 Alicino C, Giacobbe DR, Durando P, Bellina D, DI Bella AM, Paganino C, Del Bono V, Viscoli C, Icardi G, Orsi A. Increasing incidence of Clostridium difficile infections: results from a 5-year retrospective study in a large teaching hospital in the Italian region with the oldest population. Epidemiol Infect 2016;144:2517-26. [PMID: 27193828 DOI: 10.1017/S0950268816000935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
196 Lee MSL, Ramakrishna B, Moss AC, Gold HS, Branch-Elliman W. Successful treatment of fulminant Clostridioides difficile infection with emergent fecal microbiota transplantation in a patient with acute myeloid leukemia and prolonged, severe neutropenia. Transpl Infect Dis 2020;22:e13216. [PMID: 31769569 DOI: 10.1111/tid.13216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
197 Watt M, McCrea C, Johal S, Posnett J, Nazir J. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection 2016;44:599-606. [PMID: 27062378 DOI: 10.1007/s15010-016-0894-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
198 Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014;69:2901-12. [PMID: 25096079 DOI: 10.1093/jac/dku257] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
199 van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, Dekkers OM, Kuijper EJ, Keller JJ, van Prehn J. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00552-8. [PMID: 34655745 DOI: 10.1016/j.cmi.2021.09.026] [Reference Citation Analysis]
200 Grainger R, Stevens N, Humphreys H. Approaches to the detection of Clostridioides difficile in the healthcare environment. Journal of Hospital Infection 2019;103:375-81. [DOI: 10.1016/j.jhin.2019.08.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
201 Barkin JA, Sussman DA, Fifadara N, Barkin JS. Clostridium difficile Infection and Patient-Specific Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate. Dig Dis Sci 2017;62:1035-42. [DOI: 10.1007/s10620-017-4462-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
202 Biliński J, Grzesiowski P, Muszyński J, Wróblewska M, Mądry K, Robak K, Dzieciątkowski T, Wiktor-Jedrzejczak W, Basak GW. Fecal Microbiota Transplantation Inhibits Multidrug-Resistant Gut Pathogens: Preliminary Report Performed in an Immunocompromised Host. Arch Immunol Ther Exp (Warsz) 2016;64:255-8. [PMID: 26960790 DOI: 10.1007/s00005-016-0387-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
203 Soriano MM, Johnson S. Treatment of Clostridium difficile Infections. Infectious Disease Clinics of North America 2015;29:93-108. [DOI: 10.1016/j.idc.2014.11.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
204 Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, Deptuła A, Agodi A, Nuvials X, Pituch H, Wójcik-Bugajska M, Filipczak-Bryniarska I, Brzozowski B, Krzanowski M, Konturek K, Fedewicz M, Michalak M, Monpierre L, Vanhems P, Gouliouris T, Jurczyszyn A, Goldman-Mazur S, Wultańska D, Kuijper EJ, Skupień J, Biesiada G, Garlicki A. Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics (Basel) 2021;10:299. [PMID: 33805755 DOI: 10.3390/antibiotics10030299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 McFarland LV. Primary prevention of Clostridium difficile infections - how difficult can it be? Expert Rev Gastroenterol Hepatol 2017;11:507-21. [PMID: 28347160 DOI: 10.1080/17474124.2017.1312343] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
206 Kaiser AM, Hogen R, Bordeianou L, Alavi K, Wise PE, Sudan R; On behalf of the CME Committee of the SSAT. Clostridium Difficile Infection from a Surgical Perspective. J Gastrointest Surg 2015;19:1363-77. [DOI: 10.1007/s11605-015-2785-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
207 Lytvyn L, Mertz D, Sadeghirad B, Alaklobi F, Selva A, Alonso-Coello P, Johnston BC. Prevention of Clostridium difficile Infection: A Systematic Survey of Clinical Practice Guidelines. Infect Control Hosp Epidemiol 2016;37:901-8. [PMID: 27267201 DOI: 10.1017/ice.2016.104] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
208 Lübbert C, Mutters R. [Gastrointestinal infections]. Internist (Berl) 2017;58:149-69. [PMID: 28116471 DOI: 10.1007/s00108-016-0183-y] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
209 Kali A, Charles MV, Srirangaraj S. Cadazolid: A new hope in the treatment of Clostridium difficile infection. Australas Med J. 2015;8:253-262. [PMID: 26392822 DOI: 10.4066/amj.2015.2441] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
210 Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol 2015;26:305-12. [PMID: 26744587 DOI: 10.1155/2015/934594] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
211 Navalkele BD, Chopra T. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics 2018;12:11-21. [PMID: 29403263 DOI: 10.2147/BTT.S127099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
212 Baunwall SMD, Terveer EM, Dahlerup JF, Erikstrup C, Arkkila P, Vehreschild MJ, Ianiro G, Gasbarrini A, Sokol H, Kump PK, Satokari R, De Looze D, Vermeire S, Nakov R, Brezina J, Helms M, Kjeldsen J, Rode AA, Kousgaard SJ, Alric L, Trang-Poisson C, Scanzi J, Link A, Stallmach A, Kupcinskas J, Johnsen PH, Garborg K, Rodríguez ES, Serrander L, Brummer RJ, Galpérine KT, Goldenberg SD, Mullish BH, Williams HR, Iqbal TH, Ponsioen C, Kuijper EJ, Cammarota G, Keller JJ, Hvas CL. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Reg Health Eur 2021;9:100181. [PMID: 34693388 DOI: 10.1016/j.lanepe.2021.100181] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
213 Guerri S, Danti G, Frezzetti G, Lucarelli E, Pradella S, Miele V. Clostridium difficile colitis: CT findings and differential diagnosis. Radiol Med 2019;124:1185-98. [PMID: 31302848 DOI: 10.1007/s11547-019-01066-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
214 Gallo A, Cancelli C, Ceron E, Covino M, Capoluongo E, Pocino K, Ianiro G, Cammarota G, Gasbarrini A, Montalto M. Fecal calprotectin and need of multiple microbiota trasplantation infusions in Clostridium difficile infection. J Gastroenterol Hepatol 2020;35:1909-15. [PMID: 32291810 DOI: 10.1111/jgh.15072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Lee JJ, Yong D, Suk KT, Kim DJ, Woo HJ, Lee SS, Kim BS. Alteration of Gut Microbiota in Carbapenem-Resistant Enterobacteriaceae Carriers during Fecal Microbiota Transplantation According to Decolonization Periods. Microorganisms 2021;9:352. [PMID: 33578974 DOI: 10.3390/microorganisms9020352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
216 Vega AD, Heil EL, Blackman AL, Banoub M, Kristie Johnson J, Leekha S, Claeys KC. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection. Pharmacotherapy 2020;40:398-407. [PMID: 32246501 DOI: 10.1002/phar.2393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Reygner J, Charrueau C, Delannoy J, Mayeur C, Robert V, Cuinat C, Meylheuc T, Mauras A, Augustin J, Nicolis I, Modoux M, Joly F, Waligora-Dupriet AJ, Thomas M, Kapel N. Freeze-dried fecal samples are biologically active after long-lasting storage and suited to fecal microbiota transplantation in a preclinical murine model of Clostridioides difficile infection. Gut Microbes 2020;11:1405-22. [PMID: 32501140 DOI: 10.1080/19490976.2020.1759489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
218 Hong AS, Yu WY, Hong JM, Cross CL, Azab M, Ohning G, Jayaraj M. Proton pump inhibitor in upper gastrointestinal fecal microbiota transplant: A systematic review and analysis. J Gastroenterol Hepatol 2020;35:932-40. [PMID: 31830335 DOI: 10.1111/jgh.14958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
219 Hitchcock MM, Holubar M, Hogan CA, Tompkins LS, Banaei N. Dual Reporting of Clostridioides difficile PCR and Predicted Toxin Result Based on PCR Cycle Threshold Reduces Treatment of Toxin-Negative Patients without Increases in Adverse Outcomes. J Clin Microbiol 2019;57:e01288-19. [PMID: 31511334 DOI: 10.1128/JCM.01288-19] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
220 Scott KP, Antoine JM, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis. 2015;26:25877. [PMID: 25651995 DOI: 10.3402/mehd.v26.25877] [Cited by in Crossref: 67] [Cited by in F6Publishing: 81] [Article Influence: 9.6] [Reference Citation Analysis]
221 Kapel N, Thomas M, Corcos O, Mayeur C, Barbot-Trystram L, Bouhnik Y, Joly F. Practical implementation of faecal transplantation. Clin Microbiol Infect 2014;20:1098-105. [PMID: 25273614 DOI: 10.1111/1469-0691.12796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
222 Hirai J, Sakanashi D, Huh JY, Suematsu H, Hagihara M, Kato H, Yamagishi Y, Fujita J, Mikamo H. The first human clinical case of chronic osteomyelitis caused by Clostridium hydrogeniformans. Anaerobe 2017;45:138-41. [PMID: 28232120 DOI: 10.1016/j.anaerobe.2017.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
223 Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, Abu-Zidan FM, Ansaloni L, Augustin G, Bala M, Ben-Ishay O, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cortese F, Cui Y, Czepiel J, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckmann C, Eiland EH, Forrester JD, Fraga GP, Frossard JL, Fry DE, Galeiras R, Ghnnam W, Gomes CA, Griffiths EA, Guirao X, Ahmed MH, Herzog T, Kim JI, Iqbal T, Isik A, Itani KMF, Labricciosa FM, Lee YY, Juang P, Karamarkovic A, Kim PK, Kluger Y, Leppaniemi A, Lohsiriwat V, Machain GM, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Ordoñez CA, Pagani L, Petrosillo N, Portela F, Rasa K, Rems M, Sakakushev BE, Segovia-Lohse H, Sganga G, Shelat VG, Spigaglia P, Tattevin P, Tranà C, Urbánek L, Ulrych J, Viale P, Baiocchi GL, Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019;14:8. [PMID: 30858872 DOI: 10.1186/s13017-019-0228-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 15.7] [Reference Citation Analysis]
224 Kelly BJ, Tebas P. Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. Chest. 2018;153:266-277. [PMID: 28923757 DOI: 10.1016/j.chest.2017.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
225 Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May ML, Blyth CC, Ferguson JK, Blackmore TK, Riley TV, Athan E. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 2016;46:479-93. [PMID: 27062204 DOI: 10.1111/imj.13027] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 12.4] [Reference Citation Analysis]
226 Färber J, Illiger S, Berger F, Gärtner B, von Müller L, Lohmann CH, Bauer K, Grabau C, Zibolka S, Schlüter D, Geginat G. Management of a cluster of Clostridium difficile infections among patients with osteoarticular infections. Antimicrob Resist Infect Control 2017;6:22. [PMID: 28239451 DOI: 10.1186/s13756-017-0181-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
227 Fu N, Wong T. Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Curr Infect Dis Rep 2016;18. [DOI: 10.1007/s11908-016-0525-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
228 Karlowsky JA, Adam HJ, Kosowan T, Baxter MR, Nichol KA, Laing NM, Golding G, Zhanel GG. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015. Diagn Microbiol Infect Dis 2018;91:105-11. [PMID: 29456070 DOI: 10.1016/j.diagmicrobio.2018.01.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
229 Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 2015;29:109-22. [PMID: 25677705 DOI: 10.1016/j.idc.2014.11.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
230 Lagier JC, Aubry C, Delord M, Michelet P, Tissot-Dupont H, Million M, Brouqui P, Raoult D, Parola P. From Expert Protocols to Standardized Management of Infectious Diseases. Clin Infect Dis 2017;65:S12-9. [PMID: 28859349 DOI: 10.1093/cid/cix403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
231 Caupenne A, Ingrand P, Ingrand I, Forestier E, Roubaud-Baudron C, Gavazzi G, Paccalin M. Acute Clostridioides difficile Infection in Hospitalized Persons Aged 75 and Older: 30-Day Prognosis and Risk Factors for Mortality. J Am Med Dir Assoc 2020;21:110-4. [PMID: 31537480 DOI: 10.1016/j.jamda.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Thabit AK, Nicolau DP. An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes. Infect Drug Resist 2016;9:143-8. [PMID: 27390531 DOI: 10.2147/IDR.S108325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
233 Fehér C, Soriano A, Mensa J. A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection. Infect Dis Ther 2017;6:1-35. [PMID: 27910000 DOI: 10.1007/s40121-016-0140-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
234 Schmidt-Hieber M, Teschner D, Maschmeyer G, Schalk E. Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. Expert Rev Anti Infect Ther 2019;17:983-95. [PMID: 30686067 DOI: 10.1080/14787210.2019.1573670] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
235 Taylor KN, Mchale MT, Saenz CC, Plaxe SC. Diagnosis and treatment of Clostridium difficile (C. diff) colitis: Review of the literature and a perspective in gynecologic oncology. Gynecologic Oncology 2017;144:428-37. [DOI: 10.1016/j.ygyno.2016.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
236 Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017;207:166-172. [PMID: 28814204 DOI: 10.5694/mja17.00295] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 14.4] [Reference Citation Analysis]
237 Lopetuso LR, Ianiro G, Allegretti JR, Bibbò S, Gasbarrini A, Scaldaferri F, Cammarota G. Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opin Biol Ther 2020;20:343-51. [PMID: 32083498 DOI: 10.1080/14712598.2020.1733964] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
238 Todorov SD, Kang HJ, Ivanova IV, Holzapfel WH. Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis. Front Bioeng Biotechnol 2020;8:581778. [PMID: 33042979 DOI: 10.3389/fbioe.2020.581778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
239 Kampouri E, Croxatto A, Prod'hom G, Guery B. Clostridioides difficile Infection, Still a Long Way to Go. J Clin Med 2021;10:389. [PMID: 33498428 DOI: 10.3390/jcm10030389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
240 Aggeletopoulou I, Konstantakis C, Assimakopoulos SF, Triantos C. The role of the gut microbiota in the treatment of inflammatory bowel diseases. Microbial Pathogenesis 2019;137:103774. [DOI: 10.1016/j.micpath.2019.103774] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
241 Coullon H, Rifflet A, Wheeler R, Janoir C, Boneca IG, Candela T. N-Deacetylases required for muramic-δ-lactam production are involved in Clostridium difficile sporulation, germination, and heat resistance. J Biol Chem 2018;293:18040-54. [PMID: 30266804 DOI: 10.1074/jbc.RA118.004273] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
242 Yamaguchi T, Konishi H, Aoki K, Ishii Y, Chono K, Tateda K. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother 2020;26:483-91. [PMID: 32165071 DOI: 10.1016/j.jiac.2019.12.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
243 Tacke D, Wisplinghoff H, Kretzschmar A, Farowski F, Koehler P, Herweg J, Cornely O, Vehreschild M. First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe. Clinical Microbiology and Infection 2015;21:e82-4. [DOI: 10.1016/j.cmi.2015.06.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
244 Antonelli M, Martin-Loeches I, Dimopoulos G, Gasbarrini A, Vallecoccia MS. Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement. Intensive Care Med 2020;46:215-24. [PMID: 31938827 DOI: 10.1007/s00134-019-05873-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Marra F, Ng K. Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. Drugs 2015;75:1095-118. [PMID: 26113167 DOI: 10.1007/s40265-015-0422-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
246 Majeed A, Larriva MM, Iftikhar A, Mushtaq A, Campbell P, Nadeem Malik M, Rafae A, Zar MA, Kamal A, Lakhani M, Khalid NR, Zangeneh TT, Anwer F. A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients. Infect Dis Clin Pract (Baltim Md) 2020;28:10-5. [PMID: 33424210 DOI: 10.1097/ipc.0000000000000798] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
247 Popa D, Neamtu B, Mihalache M, Boicean A, Banciu A, Banciu DD, Moga DFC, Birlutiu V. Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI? J Clin Med 2021;10:5822. [PMID: 34945118 DOI: 10.3390/jcm10245822] [Reference Citation Analysis]
248 Jazmati N, Hain O, Hellmich M, Plum G, Kaasch A. PCR based detection of tcdCΔ117 in Clostridium difficile infection identifies patients at risk for recurrence - A hospital-based prospective observational study. Anaerobe 2019;57:39-44. [PMID: 30878603 DOI: 10.1016/j.anaerobe.2019.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
249 Akamine CM, Ing MB, Jackson CS, Loo LK. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. BMC Infect Dis 2016;16:316. [PMID: 27388627 DOI: 10.1186/s12879-016-1657-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
250 Bishop EJ, Tiruvoipati R, Metcalfe J, Marshall C, Botha J, Kelley PG. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study: Tigecycline combination therapy for CDI. Intern Med J 2018;48:651-60. [DOI: 10.1111/imj.13742] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
251 Cioni G, Viale P, Frasson S, Cipollini F, Menichetti F, Petrosillo N, Brunati S, Spigaglia P, Vismara C, Bielli A, Barbanti F, Landini G, Panigada G, Gussoni G, Bonizzoni E, Gesu GP; Research Department of FADOI. Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine: findings from the nationwide FADOI-PRACTICE study. BMC Infect Dis 2016;16:656. [PMID: 27825317 DOI: 10.1186/s12879-016-1961-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
252 Berro ZZ, Hamdan RH, Dandache IH, Saab MN, Karnib HH, Younes MH. Fecal microbiota transplantation for severe clostridium difficile infection after left ventricular assist device implantation: a case control study and concise review on the local and regional therapies. BMC Infect Dis 2016;16:234. [PMID: 27233894 DOI: 10.1186/s12879-016-1571-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
253 Shaikh DH, Patel H, Munshi R, Sun H, Mehershahi S, Baiomi A, Alemam A, Pirzada U, Nawaz I, Naher K, Hanumanthu S, Nayudu S. Patients with Clostridium difficile infection and prior appendectomy may be prone to worse outcomes. World J Gastrointest Surg 2021; 13(11): 1436-1447 [DOI: 10.4240/wjgs.v13.i11.1436] [Reference Citation Analysis]
254 Gordon D, Young L, Reddy S, Bergman C, Young J. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor. Journal of Hospital Infection 2016;92:173-7. [DOI: 10.1016/j.jhin.2015.10.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
255 Cusini A, Béguelin C, Stampf S, Boggian K, Garzoni C, Koller M, Manuel O, Meylan P, Mueller NJ, Hirsch HH, Weisser M, Berger C, van Delden C; Swiss Transplant Cohort Study. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. Am J Transplant 2018;18:1745-54. [PMID: 29349869 DOI: 10.1111/ajt.14640] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
256 Canibe N, O'Dea M, Abraham S. Potential relevance of pig gut content transplantation for production and research. J Anim Sci Biotechnol 2019;10:55. [PMID: 31304012 DOI: 10.1186/s40104-019-0363-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
257 Thabit AK, Alsolami MH, Baghlaf NA, Alsharekh RM, Almazmumi HA, Alselami AS, Alsubhi FA. Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines. Infection 2019;47:899-909. [PMID: 31428991 DOI: 10.1007/s15010-019-01348-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
258 Napolitano LM, Edmiston CE. Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. Surgery 2017;162:325-48. [DOI: 10.1016/j.surg.2017.01.018] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 12.2] [Reference Citation Analysis]
259 Kennedy C, Waldron C, Skally M, Gaughan L, Magee C, Burns K, Fitzpatrick F. The epidemiology of Clostridium difficile infection in a national kidney transplant center. Clin Transplant 2017;31:e12962. [DOI: 10.1111/ctr.12962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
260 Szabo BG, Duma L, Lenart KS, Kiss R, Vad E, Petrik BR, Ostorhazi E, Kadar B. Characteristics and predictors of treatment failure with intravenous tigecycline monotherapy among adult patients with severe Clostridioides (Clostridium) difficile infection: a single-centre observational cohort study. Diagn Microbiol Infect Dis 2021;99:115231. [PMID: 33099134 DOI: 10.1016/j.diagmicrobio.2020.115231] [Reference Citation Analysis]
261 Dembrovszky F, Gede N, Szakács Z, Hegyi P, Kiss S, Farkas N, Molnár Z, Imrei M, Dohos D, Péterfi Z. Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis. Infect Dis Ther 2021;10:201-11. [PMID: 33106983 DOI: 10.1007/s40121-020-00356-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
262 Neemann K, Minhas V, Loberiza FR, Freifield A. Transplant related outcomes in patients with hematopoietic stem cell transplant with Clostridium difficile associated diarrhea. Leukemia & Lymphoma 2014;56:260-2. [DOI: 10.3109/10428194.2014.917637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
263 Leber A, Hontecillas R, Abedi V, Tubau-juni N, Zoccoli-rodriguez V, Stewart C, Bassaganya-riera J. Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection. Artificial Intelligence in Medicine 2017;78:1-13. [DOI: 10.1016/j.artmed.2017.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
264 Yeh YM, Cheng HT, Le PH, Chen CC, Kuo CJ, Chen CL, Chiu CT, Chiu CH. Implementation of fecal microbiota transplantation in a medical center for recurrent or refractory Clostridioides difficile infection and report of preliminary outcome. Biomed J 2021:S2319-4170(21)00067-6. [PMID: 34118466 DOI: 10.1016/j.bj.2021.06.001] [Reference Citation Analysis]
265 Cui Y, Dong D, Zhang L, Wang D, Jiang C, Ni Q, Wang C, Mao E, Peng Y. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China. BMC Infect Dis 2019;19:961. [PMID: 31711425 DOI: 10.1186/s12879-019-4603-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
266 Thabit AK, Varugehese CA, Levine AR. Antibiotic use and duration in association with Clostridioides difficile infection in a tertiary academic medical center: A retrospective case-control study. Anaerobe 2019;59:126-30. [DOI: 10.1016/j.anaerobe.2019.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
267 Zhou Y, Zhou W, Xiao T, Chen Y, Lv T, Wang Y, Zhang S, Cai H, Chi X, Kong X, Zhou K, Shen P, Shan T, Xiao Y. Comparative genomic and transmission analysis of Clostridioides difficile between environmental, animal, and clinical sources in China. Emerg Microbes Infect 2021;:1-88. [PMID: 34756150 DOI: 10.1080/22221751.2021.2005453] [Reference Citation Analysis]
268 Oshima H, Yamazaki T, Benner L, Miki T, Michon I, Wojtkowski T, Kaibara A, Mujais S. Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects. Clin Drug Investig 2015;35:375-84. [PMID: 25972286 DOI: 10.1007/s40261-015-0291-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
269 Michal Stevens A, Esposito DH, Stoney RJ, Hamer DH, Flores-Figueroa J, Bottieau E, Connor BA, Gkrania-Klotsas E, Goorhuis A, Hynes NA, Libman M, Lopez-Velez R, McCarthy AE, von Sonnenburg F, Schwartz E, van Genderen PJ, Scott Benson L, Leung DT; GeoSentinel Surveillance Network. Clostridium difficile infection in returning travellers. J Travel Med 2017;24. [PMID: 28355613 DOI: 10.1093/jtm/taw099] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
270 Sandlund J, Estis J, Katzenbach P, Nolan N, Hinson K, Herres J, Pero T, Peterson G, Schumaker JM, Stevig C, Warren R, West T, Chow SK. Increased Clinical Specificity with Ultrasensitive Detection of Clostridioides difficile Toxins: Reduction of Overdiagnosis Compared to Nucleic Acid Amplification Tests. J Clin Microbiol 2019;57:e00945-19. [PMID: 31434726 DOI: 10.1128/JCM.00945-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
271 Lachowicz D, Pituch H, Obuch-woszczatyński P. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe 2015;31:37-41. [DOI: 10.1016/j.anaerobe.2014.09.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
272 Asgary R, Snead JA, Wahid NA, Ro V, Halim M, Stribling JC. Risks and Preventive Strategies for Clostridioides difficile Transmission to Household or Community Contacts during Transition in Healthcare Settings. Emerg Infect Dis 2021;27:1776-82. [PMID: 34152967 DOI: 10.3201/eid2707.200209] [Reference Citation Analysis]
273 Wu KS, Syue LS, Cheng A, Yen TY, Chen HM, Chiu YH, Hsu YL, Chiu CH, Su TY, Tsai WL, Chen WY, Huang CH, Hung HM, Huang LJ, Kuo HJ, Lin PC, Yang CH, Hong PL, Lee SS, Chen YS, Liu YC, Huang LM; Infectious Diseases Society of Taiwan., Medical Foundation in Memory of Dr. Deh-Lin Cheng., Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education., CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines., 5th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group. Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan. J Microbiol Immunol Infect 2020;53:191-208. [PMID: 32169531 DOI: 10.1016/j.jmii.2020.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
274 Berland M, Cadiou J, Levenez F, Galleron N, Quinquis B, Thirion F, Gauthier F, Le Chatelier E, Plaza Oñate F, Schwintner C, Rabot S, Lepage P, Ehrlich D, Doré J, Juste C. High engraftment capacity of frozen ready-to-use human fecal microbiota transplants assessed in germ-free mice. Sci Rep 2021;11:4365. [PMID: 33623056 DOI: 10.1038/s41598-021-83638-7] [Reference Citation Analysis]
275 Elbeddini A, Gerochi R. Treatment of Clostridium difficile infection in community teaching hospital: a retrospective study. J Pharm Policy Pract 2021;14:19. [PMID: 33568232 DOI: 10.1186/s40545-020-00289-1] [Reference Citation Analysis]
276 Lee C, Louie TJ, Weiss K, Valiquette L, Gerson M, Arnott W, Gorbach SL. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Can J Infect Dis Med Microbiol 2016;2016:8048757. [PMID: 27366179 DOI: 10.1155/2016/8048757] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
277 D'Ostroph AR, So TY. Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infect Drug Resist 2017;10:365-75. [PMID: 29089778 DOI: 10.2147/IDR.S119571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
278 Cammarota G, Ianiro G. Gut Microbiota and Cancer Patients: A Broad-Ranging Relationship. Mayo Clin Proc 2017;92:1605-7. [PMID: 29101928 DOI: 10.1016/j.mayocp.2017.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
279 Wenisch JM, Equiluz-Bruck S, Fudel M, Reiter I, Schmid A, Singer E, Chott A. Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use. Antimicrob Agents Chemother 2014;58:5079-83. [PMID: 24936597 DOI: 10.1128/AAC.03006-14] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
280 Polivkova S, Krutova M, Capek V, Sykorova B, Benes J. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. Int J Infect Dis 2021;103:226-33. [PMID: 33188906 DOI: 10.1016/j.ijid.2020.11.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
281 Le P, Nghiem VT, Mullen PD, Deshpande A. Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review. Infect Control Hosp Epidemiol 2018;39:412-24. [PMID: 29463339 DOI: 10.1017/ice.2017.303] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
282 Chai J, Lee CH. Management of Primary and Recurrent Clostridium difficile Infection: An Update. Antibiotics (Basel) 2018;7:E54. [PMID: 29966323 DOI: 10.3390/antibiotics7030054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
283 Chen J, Zaman A, Ramakrishna B, Olesen SW. Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank. Front Cell Infect Microbiol 2021;11:622949. [PMID: 33937092 DOI: 10.3389/fcimb.2021.622949] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
284 Spiceland CM, Khanna S, Pardi DS. Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection. J Clin Gastroenterol 2018;52:151-4. [PMID: 28009682 DOI: 10.1097/MCG.0000000000000769] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
285 Reigadas E, van Prehn J, Falcone M, Fitzpatrick F, Vehreschild MJGT, Kuijper EJ, Bouza E; European Society of Clinical Microbiology and Infectious Diseases Study Group on Clostridioides difficile (ESGCD) and Study Group for Host and Microbiota interaction (ESGHAMI). How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clin Microbiol Infect 2021:S1198-743X(21)00368-2. [PMID: 34245901 DOI: 10.1016/j.cmi.2021.06.037] [Reference Citation Analysis]
286 Asempa TE, Nicolau DP. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging 2017;12:1799-809. [PMID: 29123385 DOI: 10.2147/CIA.S149089] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 7.6] [Reference Citation Analysis]
287 Bakker GJ, Nieuwdorp M. Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. Microbiol Spectr 2017;5. [PMID: 28840809 DOI: 10.1128/microbiolspec.BAD-0008-2017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
288 Banz A, Lantz A, Riou B, Foussadier A, Miller M, Davies K, Wilcox M. Sensitivity of Single-Molecule Array Assays for Detection of Clostridium difficile Toxins in Comparison to Conventional Laboratory Testing Algorithms. J Clin Microbiol 2018;56:e00452-18. [PMID: 29898996 DOI: 10.1128/JCM.00452-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
289 López-sanromán A, Rodríguez de Santiago E, Cobo Reinoso J, del Campo Moreno R, Foruny Olcina JR, García Fernández S, García García de Paredes A, Aguilera Castro L, Ferre Aracil C, Albillos Martínez A. Resultados de la implementación de un programa multidisciplinar de trasplante de microbiota fecal por colonoscopia para el tratamiento de la infección recurrente por Clostridium difficile. Gastroenterología y Hepatología 2017;40:605-14. [DOI: 10.1016/j.gastrohep.2017.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
290 Lenoir-Wijnkoop I, Nuijten MJ, Craig J, Butler CC. Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea. Front Pharmacol. 2014;5:13. [PMID: 24596556 DOI: 10.3389/fphar.2014.00013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
291 Li H, Li WG, Zhang WZ, Yu SB, Liu ZJ, Zhang X, Wu Y, Lu JX. Antibiotic resistance of clinical isolates of Clostridioides difficile in China and its association with geographical regions and patient age. Anaerobe 2019;60:102094. [PMID: 31499177 DOI: 10.1016/j.anaerobe.2019.102094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
292 Bruxelle JF, Péchiné S, Collignon A. Immunization Strategies Against Clostridium difficile. Adv Exp Med Biol 2018;1050:197-225. [PMID: 29383671 DOI: 10.1007/978-3-319-72799-8_12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
293 Eindor-Abarbanel A, Healey GR, Jacobson K. Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood. Int J Mol Sci 2021;22:12506. [PMID: 34830388 DOI: 10.3390/ijms222212506] [Reference Citation Analysis]
294 Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild MJGT. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect 2018;48:23-9. [PMID: 29336929 DOI: 10.1016/j.medmal.2017.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
295 Mikamo H, Kondo T, Okuyama K, Marcella SW, Ruzicka DJ. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study. Anaerobe 2020;61:102139. [PMID: 31830597 DOI: 10.1016/j.anaerobe.2019.102139] [Reference Citation Analysis]
296 Goldenberg SD, Batra R, Beales I, Digby-Bell JL, Irving PM, Kellingray L, Narbad A, Franslem-Elumogo N. Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infect Dis Ther. 2018;7:71-86. [PMID: 29450831 DOI: 10.1007/s40121-018-0189-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
297 Rzucidło-Hymczak A, Hymczak H, Kędziora A, Kapelak B, Drwiła R, Plicner D. Prognostic role of perioperative acid-base disturbances on the risk of Clostridioides difficile infection in patients undergoing cardiac surgery. PLoS One 2021;16:e0248512. [PMID: 33730090 DOI: 10.1371/journal.pone.0248512] [Reference Citation Analysis]
298 Taha AE. Raw Animal Meats as Potential Sources of Clostridium difficile in Al-Jouf, Saudi Arabia. Food Sci Anim Resour 2021;41:883-93. [PMID: 34632406 DOI: 10.5851/kosfa.2021.e44] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Crobach MJT, Voor In 't Holt AF, Knetsch CW, van Dorp SM, Bras W, Harmanus C, Kuijper EJ, Vos MC. An outbreak of Clostridium difficile infections due to new PCR ribotype 826: epidemiologic and microbiologic analyses. Clin Microbiol Infect 2018;24:309.e1-4. [PMID: 28830806 DOI: 10.1016/j.cmi.2017.08.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
300 Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel. Eur J Clin Microbiol Infect Dis 2018;37:1281-8. [PMID: 29627951 DOI: 10.1007/s10096-018-3247-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
301 Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis 2016;3:23-42. [PMID: 26862400 DOI: 10.1177/2049936115622891] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 17.2] [Reference Citation Analysis]
302 Ooijevaar RE, van Nood E, Goorhuis A, Terveer EM, van Prehn J, Verspaget HW, van Beurden YH, Dijkgraaf MGW, Keller JJ. Ten-Year Follow-Up of Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection from a Randomized Controlled Trial and Review of the Literature. Microorganisms 2021;9:548. [PMID: 33800841 DOI: 10.3390/microorganisms9030548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Siehnel JT, Lavigne JE, Rightmier EA, Bossard WT, Li N, Slish JC. A Retrospective Study of Patient Factors That Indicate Provider Nonadherence to an Institutional Clostridium difficile Treatment Guideline. J Pharm Pract 2018;31:169-74. [PMID: 28569127 DOI: 10.1177/0897190017710349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
304 Misch EA, Safdar N. Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population. Infect Dis Clin North Am 2019;33:447-66. [PMID: 31005136 DOI: 10.1016/j.idc.2019.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
305 Sütterlin L, Edoo Z, Hugonnet JE, Mainardi JL, Arthur M. Peptidoglycan Cross-Linking Activity of l,d-Transpeptidases from Clostridium difficile and Inactivation of These Enzymes by β-Lactams. Antimicrob Agents Chemother 2018;62:e01607-17. [PMID: 29061738 DOI: 10.1128/AAC.01607-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
306 Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, Valencia Alijo A, Díaz-Pollán B, Rodríguez Hernández MJ, Merino De Lucas E, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez Gutiérrez B, Rodríguez-Pardo D, Ramos Martínez A, De La Torre Cisneros J, López-Medrano F, Cobo Reinoso J. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. J Clin Med 2020;10:E2. [PMID: 33374989 DOI: 10.3390/jcm10010002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
307 Terveer EM, Vendrik KE, Ooijevaar RE, Lingen EV, Boeije-Koppenol E, Nood EV, Goorhuis A, Bauer MP, van Beurden YH, Dijkgraaf MG, Mulder CJ, Vandenbroucke-Grauls CM, Seegers JF, van Prehn J, Verspaget HW, Kuijper EJ, Keller JJ. Faecal microbiota transplantation for Clostridioides difficile infection: Four years' experience of the Netherlands Donor Feces Bank. United European Gastroenterol J 2020;8:1236-47. [PMID: 32990503 DOI: 10.1177/2050640620957765] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
308 Theophilou ES, Vohra P, Gallagher MP, Poxton IR, Blakely GW. Generation of Markerless Deletions in the Nosocomial Pathogen Clostridium difficile by Induction of DNA Double-Strand Breaks. Appl Environ Microbiol 2019;85:e02055-18. [PMID: 30478235 DOI: 10.1128/AEM.02055-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Bestfater C, Vehreschild MJGT, Stallmach A, Tüffers K, Erhardt A, Frank T, Glück T, Goeser F, Sellge G, Solbach P, Eisenlohr H, Storr M; German Clinical Microbiome Study Group (GCMSG). Clinical effectiveness of bidirectional fecal microbiota transfer in the treatment of recurrent Clostridioides difficile infections. Dig Liver Dis 2021;53:706-11. [PMID: 33744169 DOI: 10.1016/j.dld.2021.02.022] [Reference Citation Analysis]
310 Mullane KM, Dubberke ER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant 2019;33:e13564. [PMID: 31002420 DOI: 10.1111/ctr.13564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
311 Björkqvist O, Rangel I, Serrander L, Magnusson C, Halfvarson J, Norén T, Bergman-Jungeström M. Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection. PLoS One 2021;16:e0249861. [PMID: 33836037 DOI: 10.1371/journal.pone.0249861] [Reference Citation Analysis]
312 Tschudin-sutter S, Tamma PD, Milstone AM, Perl TM. The Prediction of Complicated Clostridium difficile Infections in Children. Infect Control Hosp Epidemiol 2014;35:901-3. [DOI: 10.1086/676874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
313 Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, Hvas CL. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 2020;29-30:100642. [PMID: 33437951 DOI: 10.1016/j.eclinm.2020.100642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
314 Rao K, Young VB. Probiotics for Prevention of Clostridium difficile Infection in Hospitalized Patients: Is the Jury Still Out? Gastroenterology 2017;152:1817-9. [PMID: 28461190 DOI: 10.1053/j.gastro.2017.04.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
315 Casari E, De Luca C, Calabrò M, Scuderi C, Daleno C, Ferrario A. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control 2018;7:40. [PMID: 29564088 DOI: 10.1186/s13756-018-0332-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
316 Bouza E, Aguado JM, Alcalá L, Almirante B, Alonso-Fernández P, Borges M, Cobo J, Guardiola J, Horcajada JP, Maseda E, Mensa J, Merchante N, Muñoz P, Pérez Sáenz JL, Pujol M, Reigadas E, Salavert M, Barberán J. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). Rev Esp Quimioter 2020;33:151-75. [PMID: 32080996 DOI: 10.37201/req/2065.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
317 Vigvári S, Vincze Á, Solt J, Sipos D, Feiszt Z, Kovács B, Kappéter Á, Péterfi Z. Experiences with fecal microbiota transplantation in Clostridium difficile infections via upper gastrointestinal tract. Acta Microbiol Immunol Hung 2019;66:179-88. [PMID: 30585500 DOI: 10.1556/030.65.2018.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
318 Khanna S, Shin A, Kelly CP. Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clinical Gastroenterology and Hepatology 2017;15:166-74. [DOI: 10.1016/j.cgh.2016.10.024] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
319 Reintam Blaser A, Deane AM, Fruhwald S. Diarrhoea in the critically ill: . Current Opinion in Critical Care 2015;21:142-53. [DOI: 10.1097/mcc.0000000000000188] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
320 Kassam Z, Lee CH, Hunt RH. Review of the Emerging Treatment of Clostridium difficile Infection with Fecal Microbiota Transplantation and Insights into Future Challenges. Clinics in Laboratory Medicine 2014;34:787-98. [DOI: 10.1016/j.cll.2014.08.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
321 Reigadas E, Bouza E, Olmedo M, Vázquez-Cuesta S, Villar-Gómara L, Alcalá L, Marín M, Rodríguez-Fernández S, Valerio M, Muñoz P. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. J Hosp Infect 2020;105:319-24. [PMID: 31883938 DOI: 10.1016/j.jhin.2019.12.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
322 Jakobs F, Wingen-Heimann SM, Jeck J, Kron A, Cornely OA, Kron F. A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany. BMC Health Serv Res 2021;21:939. [PMID: 34496836 DOI: 10.1186/s12913-021-06970-8] [Reference Citation Analysis]
323 Nale JY, Chutia M, Cheng JKJ, Clokie MRJ. Refining the Galleria mellonella Model by Using Stress Marker Genes to Assess Clostridioides difficile Infection and Recuperation during Phage Therapy. Microorganisms 2020;8:E1306. [PMID: 32867060 DOI: 10.3390/microorganisms8091306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S, Wultańska D, Garlicki A, Biesiada G. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019;38:1211-21. [PMID: 30945014 DOI: 10.1007/s10096-019-03539-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 29.0] [Reference Citation Analysis]
325 Krutova M, Matejkova J, Drevinek P, Kuijper EJ, Nyc O; on behalf of the study group. Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. Eur J Clin Microbiol Infect Dis 2017;36:2251-8. [DOI: 10.1007/s10096-017-3055-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
326 Kumar V, Fischer M. Expert opinion on fecal microbiota transplantation for the treatment of Clostridioides difficile infection and beyond. Expert Opin Biol Ther. 2020;20:73-81. [PMID: 31690143 DOI: 10.1080/14712598.2020.1689952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
327 Rzucidło-Hymczak A, Hymczak H, Olechowska-Jarząb A, Gorczyca A, Kapelak B, Drwiła R, Plicner D. Clostridioides difficile infection after cardiac surgery: Assessment of prevalence, risk factors and clinical outcomes-retrospective study. PeerJ 2020;8:e9972. [PMID: 33062429 DOI: 10.7717/peerj.9972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
328 Bakken JS. Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations. Microb Ecol Health Dis 2015;26:27657. [PMID: 26031677 DOI: 10.3402/mehd.v26.27657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
329 Mileto S, Das A, Lyras D, Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI. Enterotoxic Clostridia: Clostridioides difficile Infections. Microbiol Spectr 2019;7. [DOI: 10.1128/microbiolspec.gpp3-0015-2018] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
330 Abad CLR, Safdar N. A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea. Gastroenterol Clin North Am 2021;50:323-40. [PMID: 34024444 DOI: 10.1016/j.gtc.2021.02.010] [Reference Citation Analysis]
331 Salavert Lletí M. Choice of treatment in Clostridium difficile-associated diarrhoea: Clinical practice guidelines or risk classifications. Enferm Infecc Microbiol Clin 2017;35:613-6. [PMID: 29179981 DOI: 10.1016/j.eimc.2017.11.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
332 Petrosillo N, Granata G, Cataldo MA. Novel Antimicrobials for the Treatment of Clostridium difficile Infection. Front Med (Lausanne) 2018;5:96. [PMID: 29713630 DOI: 10.3389/fmed.2018.00096] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
333 Kulecka M, Waker E, Ambrozkiewicz F, Paziewska A, Skubisz K, Cybula P, Targoński Ł, Mikula M, Walewski J, Ostrowski J. Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection. BMC Microbiol 2021;21:36. [PMID: 33509087 DOI: 10.1186/s12866-021-02090-9] [Reference Citation Analysis]
334 Roshan N, Hammer KA, Riley TV. Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Anaerobe 2018;49:103-11. [DOI: 10.1016/j.anaerobe.2018.01.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
335 Barron J, Lattes A, Marcus EL. Rash induced by enteral vancomycin therapy in an older patient in a long-term care ventilator unit: case report and review of the literature. Allergy Asthma Clin Immunol 2018;14:73. [PMID: 30450116 DOI: 10.1186/s13223-018-0293-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
336 Huttner BD, de Lastours V, Wassenberg M, Maharshak N, Mauris A, Galperine T, Zanichelli V, Kapel N, Bellanger A, Olearo F, Duval X, Armand-Lefevre L, Carmeli Y, Bonten M, Fantin B, Harbarth S; R-Gnosis WP3 study group. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect 2019;25:830-8. [PMID: 30616014 DOI: 10.1016/j.cmi.2018.12.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 18.7] [Reference Citation Analysis]
337 Fang H, Fu L, Wang J. Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018;2018:8941340. [PMID: 30302341 DOI: 10.1155/2018/8941340] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
338 Lübbert C, Salzberger B, Mössner J. [Fecal microbiota transplantation]. Internist (Berl) 2017;58:456-68. [PMID: 28235986 DOI: 10.1007/s00108-017-0203-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
339 Di X, Bai N, Zhang X, Liu B, Ni W, Wang J, Wang K, Liang B, Liu Y, Wang R. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 2015;19:339-49. [PMID: 26001980 DOI: 10.1016/j.bjid.2015.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
340 Zahid U, Sagar F, Al Mohajer M, Majeed A. Management of Recurrent Clostridium difficile Infection During Intensive Chemotherapy and Stem Cell Transplantation for Leukemia: Case with Literature Review. Cureus 2018;10:e2413. [PMID: 29872594 DOI: 10.7759/cureus.2413] [Reference Citation Analysis]
341 Archbald-Pannone LR. Quantitative Fecal Lactoferrin as a Biomarker for Severe Clostridium difficile Infection in Hospitalized Patients. J Geriatr Palliat Care 2014;2:3. [PMID: 25401164 DOI: 10.13188/2373-1133.1000006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
342 Chilton C, Pickering D, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clinical Microbiology and Infection 2018;24:476-82. [DOI: 10.1016/j.cmi.2017.11.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
343 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
344 Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset. J Infect Chemother 2019;25:615-20. [PMID: 30987950 DOI: 10.1016/j.jiac.2019.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
345 Riley TV, Lyras D, Douce GR. Status of vaccine research and development for Clostridium difficile. Vaccine 2019;37:7300-6. [PMID: 30902484 DOI: 10.1016/j.vaccine.2019.02.052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
346 D'Odorico I, Di Bella S, Monticelli J, Giacobbe DR, Boldock E, Luzzati R. Role of fecal microbiota transplantation in inflammatory bowel disease. J Dig Dis 2018;19:322-34. [PMID: 29696802 DOI: 10.1111/1751-2980.12603] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
347 Gauzit R, Castan B, Bonnet E, Bru JP, Cohen R, Diamantis S, Faye A, Hitoto H, Issa N, Lebeaux D, Lesprit P, Maulin L, Poitrenaud D, Raymond J, Strady C, Varon E, Verdon R, Vuotto F, Welker Y, Stahl JP. Anti-infectious treatment duration: The SPILF and GPIP French guidelines and recommendations. Infect Dis Now 2021;51:114-39. [PMID: 34158156 DOI: 10.1016/j.idnow.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
348 Chatedaki C, Voulgaridi I, Kachrimanidou M, Hrabak J, Papagiannitsis C, Petinaki E. Antimicrobial susceptibility and mechanisms of resistance of Greek Clostridium difficile clinical isolates. Journal of Global Antimicrobial Resistance 2019;16:53-8. [DOI: 10.1016/j.jgar.2018.09.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
349 Simmerlein R, Basta A, Gosch M. Clostridium-difficile-Infektion bei geriatrischen Patienten. Z Gerontol Geriat 2016;49:743-61. [DOI: 10.1007/s00391-016-1143-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
350 Fuereder T, Koni D, Gleiss A, Kundi M, Makristathis A, Zielinski C, Steininger C. Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients. Sci Rep 2016;6:31498. [PMID: 27510591 DOI: 10.1038/srep31498] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
351 Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, Allegretti JR, Bibbò S, Sokol H, Zhang F, Fischer M, Costello SP, Keller JJ, Masucci L, van Prehn J, Quaranta G, Quraishi MN, Segal J, Kao D, Satokari R, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota G. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut 2020;69:1555-63. [PMID: 32620549 DOI: 10.1136/gutjnl-2020-321829] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
352 Guery B, Galperine T, Barbut F. Clostridioides difficile: diagnosis and treatments. BMJ. 2019;366:l4609. [PMID: 31431428 DOI: 10.1136/bmj.l4609] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
353 Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2016;13:150-160. [PMID: 26860266 DOI: 10.1038/nrgastro.2015.220] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 13.7] [Reference Citation Analysis]
354 Spigaglia P, Mastrantonio P, Barbanti F. Antibiotic Resistances of Clostridium difficile. Adv Exp Med Biol 2018;1050:137-59. [PMID: 29383668 DOI: 10.1007/978-3-319-72799-8_9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
355 Cornely OA, Watt M, McCrea C, Goldenberg SD, De Nigris E. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness. J Antimicrob Chemother 2018;73:2529-39. [PMID: 29800295 DOI: 10.1093/jac/dky184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
356 Hidalgo-Villeda F, Tzoc E, Torres L, Bu E, Rodríguez C, Quesada-Gómez C. Diversity of multidrug-resistant epidemic Clostridium difficile NAP1/RT027/ST01 strains in tertiary hospitals from Honduras. Anaerobe 2018;52:75-8. [PMID: 29890209 DOI: 10.1016/j.anaerobe.2018.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
357 Hamada M, Yamaguchi T, Ishii Y, Chono K, Tateda K. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile. J Infect Chemother 2020;26:685-92. [PMID: 32224190 DOI: 10.1016/j.jiac.2020.02.014] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
358 Hassoun A. Clostridium difficile associated disease. BMJ 2018;363:k4369. [PMID: 30373736 DOI: 10.1136/bmj.k4369] [Reference Citation Analysis]
359 Lei DK, Ollech JE, Andersen M, Weisshof R, Zmeter N, Sossenheimer P, Rubin DT. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol 2019;114:1904-8. [PMID: 31714359 DOI: 10.14309/ajg.0000000000000460] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
360 Zanella Terrier MC, Simonet ML, Bichard P, Frossard JL. Recurrent Clostridium difficile infections: The importance of the intestinal microbiota. World J Gastroenterol 2014; 20(23): 7416-7423 [PMID: 24966611 DOI: 10.3748/wjg.v20.i23.7416] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
361 Fitzpatrick F, Skally M, Brady M, Burns K, Rooney C, Wilcox MH. European Practice for CDI Treatment. Adv Exp Med Biol 2018;1050:117-35. [PMID: 29383667 DOI: 10.1007/978-3-319-72799-8_8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
362 Falcone M, Tiseo G, Iraci F, Raponi G, Goldoni P, Delle Rose D, Santino I, Carfagna P, Murri R, Fantoni M, Fontana C, Sanguinetti M, Farcomeni A, Antonelli G, Aceti A, Mastroianni C, Andreoni M, Cauda R, Petrosillo N, Venditti M. Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. Clin Microbiol Infect 2019;25:474-80. [PMID: 29964230 DOI: 10.1016/j.cmi.2018.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
363 Baunwall SMD, Dahlerup JF, Engberg JH, Erikstrup C, Helms M, Juel MA, Kjeldsen J, Nielsen HL, Nilsson AC, Rode AA, Vinter-Jensen L, Hvas CL. Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scand J Gastroenterol 2021;56:1056-77. [PMID: 34261379 DOI: 10.1080/00365521.2021.1922749] [Reference Citation Analysis]
364 Ramsauer B, König C, Sabelhaus T, Ockenga J, Otte J. Stuhltransplantation beim Rezidiv der Clostridium-difficile-Kolitis. MMW - Fortschritte der Medizin 2016;158:17-20. [DOI: 10.1007/s15006-016-8305-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
365 Ivarsson ME, Leroux JC, Castagner B. Investigational new treatments for Clostridium difficile infection. Drug Discov Today 2015;20:602-8. [PMID: 25499664 DOI: 10.1016/j.drudis.2014.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
366 Gil F, Calderón IL, Fuentes JA, Paredes-Sabja D. Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies. Future Microbiol 2018;13:469-82. [PMID: 29464969 DOI: 10.2217/fmb-2017-0203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
367 Coullon H, Rifflet A, Wheeler R, Janoir C, Boneca IG, Candela T. Peptidoglycan analysis reveals that synergistic deacetylase activity in vegetative Clostridium difficile impacts the host response. J Biol Chem 2020;295:16785-96. [PMID: 32978253 DOI: 10.1074/jbc.RA119.012442] [Reference Citation Analysis]
368 Bozkurt HS, Kara B. Combination of oral vancomycin and intra-colonic vancomycin: Successful treatment of complicated pseudomembranous colitis in a child patient. SAGE Open Med Case Rep 2019;7:2050313X19838442. [PMID: 30911393 DOI: 10.1177/2050313X19838442] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
369 Milani C, Ticinesi A, Gerritsen J, Nouvenne A, Lugli GA, Mancabelli L, Turroni F, Duranti S, Mangifesta M, Viappiani A, Ferrario C, Maggio M, Lauretani F, De Vos W, van Sinderen D, Meschi T, Ventura M. Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci Rep 2016;6:25945. [PMID: 27166072 DOI: 10.1038/srep25945] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 19.7] [Reference Citation Analysis]
370 Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Augustin G, Bala M, Barbut F, Ben-Ishay O, Bhangu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Nord CE, Ordoñez CA, Júnior GA, Petrosillo N, Portela F, Puri BK, Ray A, Raza M, Rems M, Sakakushev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Tranà C, Uhl W, Urbánek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg 2015;10:38. [PMID: 26300956 DOI: 10.1186/s13017-015-0033-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
371 Chahine EB. The Rise and Fall of Metronidazole for Clostridium difficile Infection. Ann Pharmacother 2018;52:600-2. [PMID: 29424238 DOI: 10.1177/1060028018757446] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
372 Kidane B, Lung K, McCreery G, El-Khatib C, Ott MC, Hernandez-Alejandro R, Vinden C, Gray D, Parry NG, Leslie KA, Mele TS. Early Rescue from Acute Severe Clostridium Difficile: A Novel Treatment Strategy. Surg Infect (Larchmt) 2018;19:78-82. [PMID: 29227201 DOI: 10.1089/sur.2017.147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
373 Moon HW, Kim HN, Kim JY, Hur M, Kim H, Yun YM. Performance of the artus C. difficile QS-RGQ Kit for the detection of toxigenic Clostridium difficile. Clin Biochem 2017;50:84-7. [PMID: 27556286 DOI: 10.1016/j.clinbiochem.2016.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
374 Fawley J, Napolitano LM. Vancomycin Enema in the Treatment of Clostridium difficile Infection. Surg Infect (Larchmt) 2019;20:311-6. [PMID: 30716016 DOI: 10.1089/sur.2018.238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
375 Kim J, Kim H, Oh HJ, Kim HS, Hwang YJ, Yong D, Jeong SH, Lee K. Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection. Ann Lab Med 2017;37:53-7. [PMID: 27834066 DOI: 10.3343/alm.2017.37.1.53] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
376 Benoist H, de La Blanchardière A, Flatres A, Isnard C, Thibon P, Saint-Lorant G. Effect of a prospective audit with intervention and feedback on Clostridioides difficile infection management. Int J Clin Pharm 2020;42:923-30. [PMID: 32410207 DOI: 10.1007/s11096-020-01050-z] [Reference Citation Analysis]
377 Rubio-Terrés C, Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Lletí M, Toledo A, Anguita P, Rubio-Rodríguez D, Watt M, Gani R. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis 2015;34:2213-23. [PMID: 26407619 DOI: 10.1007/s10096-015-2472-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
378 Bouza E, Del Vecchio MG, Reigadas E. Spectrum of Clostridium difficile infections: Particular clinical situations. Anaerobe 2016;37:3-7. [PMID: 26700883 DOI: 10.1016/j.anaerobe.2015.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
379 Zhang XY, Wang YZ, Li XL, Hu H, Liu HF, Li D, Xiao YM, Zhang T. Safety of fecal microbiota transplantation in Chinese children: A single-center retrospective study. World J Clin Cases 2018; 6(16): 1121-1127 [PMID: 30613670 DOI: 10.12998/wjcc.v6.i16.1121] [Reference Citation Analysis]
380 Granata G, Bartoloni A, Codeluppi M, Contadini I, Cristini F, Fantoni M, Ferraresi A, Fornabaio C, Grasselli S, Lagi F, Masucci L, Puoti M, Raimondi A, Taddei E, Trapani FF, Viale P, Johnson S, Petrosillo N, On Behalf Of The CloVid Study Group. The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid). J Clin Med 2020;9:E3855. [PMID: 33260943 DOI: 10.3390/jcm9123855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
381 Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc. 2016;49:257-265. [PMID: 26956193 DOI: 10.5946/ce.2015.117] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 19.7] [Reference Citation Analysis]
382 Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH. SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother 2015;70:182-9. [PMID: 25190720 DOI: 10.1093/jac/dku324] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
383 Stavropoulou E, Bezirtzoglou E. Probiotics in Medicine: A Long Debate. Front Immunol 2020;11:2192. [PMID: 33072084 DOI: 10.3389/fimmu.2020.02192] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
384 Kleinman L, Talbot GH, Hunsche E, Schüler R, Nord CE. The CDI-DaySyms: Content Development of a New Patient-Reported Outcome Questionnaire for Symptoms of Clostridium difficile Infection. Value in Health 2018;21:441-8. [DOI: 10.1016/j.jval.2017.08.3017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
385 Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313:398-408. [PMID: 25626036 DOI: 10.1001/jama.2014.17103] [Cited by in Crossref: 274] [Cited by in F6Publishing: 237] [Article Influence: 39.1] [Reference Citation Analysis]
386 Bouza E, Alcalá L, Reigadas E. Optimizing the diagnostic testing of Clostridium difficile infection. Expert Rev Anti Infect Ther 2016;14:801-8. [PMID: 27462827 DOI: 10.1080/14787210.2016.1216313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
387 Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health 2017;7:010417. [PMID: 28607673 DOI: 10.7189/jogh.07.010417] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
388 Leitner E, Schreiner E, Neuhold M, Bozic M, Pux C, Pichler G, Schippinger W, Steinmetz I, Krause R, Zollner-Schwetz I. Low prevalence of Clostridium difficile colonization in patients in long-term care facilities in Graz, Austria: A point-prevalence study. Am J Infect Control 2020;48:1144-7. [PMID: 31917013 DOI: 10.1016/j.ajic.2019.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
389 Cornely OA, Vehreschild MJGT, Adomakoh N, Georgopali A, Karas A, Kazeem G, Guery B. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. Eur J Clin Microbiol Infect Dis 2019;38:1187-94. [PMID: 30911926 DOI: 10.1007/s10096-019-03525-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
390 Nanki K, Mizuno S, Matsuoka K, Ono K, Sugimoto S, Kiyohara H, Arai M, Nakashima M, Takeshita K, Saigusa K, Senoh M, Fukuda T, Naganuma M, Kato H, Suda W, Hattori M, Kanai T. Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis. Intest Res 2018;16:142-6. [PMID: 29422809 DOI: 10.5217/ir.2018.16.1.142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
391 Abdali ZI, Roberts TE, Barton P, Hawkey PM. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection. EClinicalMedicine 2020;24:100420. [PMID: 32637898 DOI: 10.1016/j.eclinm.2020.100420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
392 Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers 2016;2:16020. [PMID: 27158839 DOI: 10.1038/nrdp.2016.20] [Cited by in Crossref: 301] [Cited by in F6Publishing: 241] [Article Influence: 50.2] [Reference Citation Analysis]
393 Nagy E. What do we know about the diagnostics, treatment and epidemiology of Clostridioides (Clostridium) difficile infection in Europe? J Infect Chemother 2018;24:164-70. [PMID: 29289484 DOI: 10.1016/j.jiac.2017.12.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
394 Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569-80. [PMID: 28087657 DOI: 10.1136/gutjnl-2016-313017] [Cited by in Crossref: 425] [Cited by in F6Publishing: 365] [Article Influence: 85.0] [Reference Citation Analysis]
395 Nuijten MJ, Keller JJ, Visser CE, Redekop K, Claassen E, Speelman P, Pronk MH. Cost-effectiveness in Clostridium difficile treatment decision-making. World J Clin Cases 2015; 3(11): 935-941 [PMID: 26601096 DOI: 10.12998/wjcc.v3.i11.935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
396 Wang R, Suo L, Chen HX, Song LJ, Shen YY, Luo YP. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from the Chinese People’s Liberation Army General Hospital in China. International Journal of Infectious Diseases 2018;67:86-91. [DOI: 10.1016/j.ijid.2017.07.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
397 Bouza E, Cobo J, Rodríguez-Hernández MJ, Salavert M, Horcajada JP, Iribarren JA, Obi E, Lozano V, Maratia S, Cuesta M, Uría E, Limón E. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study. Rev Esp Quimioter 2021;34:126-35. [PMID: 33618513 DOI: 10.37201/req/135.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Appaneal HJ, Caffrey AR, LaPlante KL. What Is the Role for Metronidazole in the Treatment of Clostridium difficile Infection? Results From a National Cohort Study of Veterans With Initial Mild Disease. Clin Infect Dis 2019;69:1288-95. [PMID: 30561531 DOI: 10.1093/cid/ciy1077] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
399 Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L, Maleki A, Kouhsari E. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2020;9:158. [PMID: 32977835 DOI: 10.1186/s13756-020-00815-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
400 Haller W, Ledder O, Lewindon PJ, Couper R, Gaskin KJ, Oliver M. Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications: Gastrointestinal disease in cystic fibrosis. J Gastroenterol Hepatol 2014;29:1344-55. [DOI: 10.1111/jgh.12546] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
401 Li YT, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther. 2016;43:445-457. [PMID: 26662643 DOI: 10.1111/apt.13492] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 13.1] [Reference Citation Analysis]
402 Suárez-Bode L, Barrón R, Pérez JL, Mena A. Increasing prevalence of the epidemic ribotype 106 in healthcare facility-associated and community-associated Clostridioides difficile infection. Anaerobe 2019;55:124-9. [PMID: 30550807 DOI: 10.1016/j.anaerobe.2018.12.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
403 Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, Sokol H, Kump P, Satokari R, Kahn SA, Kao D, Arkkila P, Kuijper EJ, Vehreschild MJG, Pintus C, Lopetuso L, Masucci L, Scaldaferri F, Terveer EM, Nieuwdorp M, López-Sanromán A, Kupcinskas J, Hart A, Tilg H, Gasbarrini A. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 2019;68:2111-21. [PMID: 31563878 DOI: 10.1136/gutjnl-2019-319548] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 41.7] [Reference Citation Analysis]
404 Xu R, Tan C, Zhu J, Zeng X, Gao X, Wu Q, Chen Q, Wang H, Zhou H, He Y, Pan S, Yin J. Dysbiosis of the intestinal microbiota in neurocritically ill patients and the risk for death. Crit Care 2019;23:195. [PMID: 31151471 DOI: 10.1186/s13054-019-2488-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
405 Cheng Y, Fischer M. Clinical management of severe, fulminant, and refractory Clostridioides difficile infection. Expert Review of Anti-infective Therapy 2020;18:323-33. [DOI: 10.1080/14787210.2020.1730814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
406 Vigvári S, Nemes Z, Vincze Á, Solt J, Sipos D, Feiszt Z, Kappéter Á, Kovács B, Péterfi Z. Experience with fecal microbiota transplantation in the treatment of Clostridium difficile infection. Orvosi Hetilap 2014;155:1758-62. [DOI: 10.1556/oh.2014.30020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
407 Barbut F, Collignon A, Butel MJ, Bourlioux P. [Fecal microbiota transplantation: review]. Ann Pharm Fr 2015;73:13-21. [PMID: 25577013 DOI: 10.1016/j.pharma.2014.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
408 Minotti C, Barbieri E, Giaquinto C, Donà D. Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles. Pathogens 2021;10:1343. [PMID: 34684291 DOI: 10.3390/pathogens10101343] [Reference Citation Analysis]
409 Kimura T, Stanhope S, Sugitani T. Excess length of hospital stay, mortality and cost attributable to Clostridioides (Clostridium) difficile infection and recurrence: a nationwide analysis in Japan. Epidemiol Infect 2020;148:e65. [PMID: 32115019 DOI: 10.1017/S0950268820000606] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
410 Robin C, Héquette-Ruz R, Guery B, Boyle E, Herbaux C, Galperine T. Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable? Med Mal Infect 2017;47:532-9. [PMID: 28823390 DOI: 10.1016/j.medmal.2017.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
411 Yoldaş Ö, Altındiş M, Cufalı D, Aşık G, Keşli R. A Diagnostic Algorithm for the Detection of Clostridium difficile-Associated Diarrhea. Balkan Med J 2016;33:80-6. [PMID: 26966622 DOI: 10.5152/balkanmedj.2015.15159] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
412 Coia JE, Kuijper EJ. The ESCMID Study Group for Clostridium difficile: History, Role and Perspectives. Adv Exp Med Biol 2018;1050:245-54. [PMID: 29383673 DOI: 10.1007/978-3-319-72799-8_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
413 Tschudin-Sutter S, Braissant O, Erb S, Stranden A, Bonkat G, Frei R, Widmer AF. Growth Patterns of Clostridium difficile - Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study. PLoS One 2016;11:e0161711. [PMID: 27598309 DOI: 10.1371/journal.pone.0161711] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
414 Daida A, Yoshihara H, Inai I, Hasegawa D, Ishida Y, Urayama KY, Manabe A. Risk Factors for Hospital-acquired Clostridium difficile Infection Among Pediatric Patients With Cancer. Journal of Pediatric Hematology/Oncology 2017;39:e167-72. [DOI: 10.1097/mph.0000000000000742] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
415 Basson AR, Gomez-Nguyen A, Menghini P, Buttó LF, Di Martino L, Aladyshkina N, Osme A, LaSalla A, Fischer D, Ezeji JC, Erkkila HL, Brennan CJ, Lam M, Rodriguez-Palacios A, Cominelli F. Human Gut Microbiome Transplantation in Ileitis Prone Mice: A Tool for the Functional Characterization of the Microbiota in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 2020;26:347-59. [PMID: 31750921 DOI: 10.1093/ibd/izz242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
416 Schneider KM, Wirtz TH, Kroy D, Albers S, Neumann UP, Strowig T, Sellge G, Trautwein C. Successful Fecal Microbiota Transplantation in a Patient with Severe Complicated Clostridium difficile Infection after Liver Transplantation. Case Rep Gastroenterol 2018;12:76-84. [PMID: 29606940 DOI: 10.1159/000481937] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
417 Church DL. Selected Topics in Anaerobic Bacteriology. Microbiol Spectr 2016;4. [PMID: 27726792 DOI: 10.1128/microbiolspec.DMIH2-0015-2015] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
418 Staley C, Khoruts A, Sadowsky MJ. Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans. Arch Med Res 2017;48:766-73. [PMID: 29183720 DOI: 10.1016/j.arcmed.2017.11.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
419 Bonnassot P, Barben J, Tetu J, Bador J, Bonniaud P, Manckoundia P, Putot A. Clostridioides difficile infection after pneumonia in older patients: Which antibiotic is at lower risk? J Hosp Infect 2020:S0195-6701(20)30240-1. [PMID: 32437825 DOI: 10.1016/j.jhin.2020.05.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
420 Bourlioux P; workgroup of the French Academy of Pharmacy Faecal microbiota transplantation: Key points to consider. Ann Pharm Fr. 2015;73:163-168. [PMID: 25747146 DOI: 10.1016/j.pharma.2015.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
421 Khanafer N, Barbut F, Eckert C, Perraud M, Demont C, Luxemburger C, Vanhems P. Factors predictive of severe Clostridium difficile infection depend on the definition used. Anaerobe 2016;37:43-8. [DOI: 10.1016/j.anaerobe.2015.08.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
422 Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver 2019;13:16-24. [PMID: 30400734 DOI: 10.5009/gnl18071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
423 Petrosillo N, Cataldo MA. Clostridioides difficile Infection: A Room for Multifaceted Interventions. J Clin Med 2020;9:E4114. [PMID: 33419243 DOI: 10.3390/jcm9124114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
424 Larrainzar-Coghen T, Rodriguez-Pardo D, Puig-Asensio M, Rodríguez V, Ferrer C, Bartolomé R, Pigrau C, Fernández-Hidalgo N, Pumarola T, Almirante B. First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis. Eur J Clin Microbiol Infect Dis 2016;35:371-8. [PMID: 26753991 DOI: 10.1007/s10096-015-2549-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
425 Pouch SM, Friedman-Moraco RJ. Prevention and Treatment of Clostridium difficile-Associated Diarrhea in Solid Organ Transplant Recipients. Infect Dis Clin North Am 2018;32:733-48. [PMID: 30146033 DOI: 10.1016/j.idc.2018.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
426 Bibbò S, Lopetuso LR, Ianiro G, Di Rienzo T, Gasbarrini A, Cammarota G. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J Immunol Res 2014;2014:462740. [PMID: 24995345 DOI: 10.1155/2014/462740] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
427 Guery B. Clostridium difficile infection trials: what is the primary endpoint? Lancet Infect Dis 2019;19:219-20. [PMID: 30709664 DOI: 10.1016/S1473-3099(18)30626-1] [Reference Citation Analysis]
428 Padua D, Pothoulakis C. Novel approaches to treating Clostridium difficile-associated colitis. Expert Rev Gastroenterol Hepatol 2016;10:193-204. [PMID: 26643655 DOI: 10.1586/17474124.2016.1109444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
429 Aoki K, Takeda S, Miki T, Ishii Y, Tateda K. Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016. Antimicrob Agents Chemother 2019:AAC. [PMID: 31527041 DOI: 10.1128/AAC.01259-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
430 Turner NA, Saullo JL, Polage CR. Healthcare associated diarrhea, not Clostridioides difficile. Curr Opin Infect Dis 2020;33:319-26. [PMID: 32657969 DOI: 10.1097/QCO.0000000000000653] [Reference Citation Analysis]
431 Weichert S, Simon A, von Müller L, Adam R, Schroten H. Clostridium-difficile-assoziierte Infektionen im Kindes- und Jugendalter. Monatsschr Kinderheilkd 2015;163:427-36. [DOI: 10.1007/s00112-014-3253-z] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
432 Dylis A, Boureau AS, Coutant A, Batard E, Javaudin F, Berrut G, de Decker L, Chapelet G. Antibiotics prescription and guidelines adherence in elderly: impact of the comorbidities. BMC Geriatr 2019;19:291. [PMID: 31664914 DOI: 10.1186/s12877-019-1265-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
433 Keller PM, Weber MH. Rational Therapy of Clostridium difficile Infections. Viszeralmedizin 2014;30:304-9. [PMID: 26288096 DOI: 10.1159/000366302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
434 Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis 2019;19:265-74. [PMID: 30709665 DOI: 10.1016/S1473-3099(18)30614-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
435 Elangovan A, Allegretti JR, Fischer M. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. Expert Opin Biol Ther 2019;19:1343-55. [PMID: 31570017 DOI: 10.1080/14712598.2019.1673725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
436 Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, Stroehlein JR, Okhuysen PC, Wang Y. Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. Eur J Gastroenterol Hepatol 2019;31:128-34. [PMID: 30339561 DOI: 10.1097/MEG.0000000000001288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
437 Scheeler A. Where Stool is a Drug: International Approaches to Regulating the use of Fecal Microbiota for Transplantation. J Law Med Ethics 2019;47:524-40. [PMID: 31957572 DOI: 10.1177/1073110519897729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
438 Rashid M, Dalhoff A, Weintraub A, Nord CE. In vitro activity of MCB3681 against Clostridium difficile strains. Anaerobe 2014;28:216-9. [DOI: 10.1016/j.anaerobe.2014.07.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
439 Fehér C, Múñez Rubio E, Merino Amador P, Delgado-Iribarren Garcia-Campero A, Salavert M, Merino E, Maseda Garrido E, Díaz-Brito V, Álvarez MJ, Mensa J. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort. Eur J Clin Microbiol Infect Dis 2017;36:295-303. [PMID: 27718071 DOI: 10.1007/s10096-016-2802-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
440 Kechagias KS, Chorepsima S, Triarides NA, Falagas ME. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis 2020;39:1053-8. [DOI: 10.1007/s10096-019-03756-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
441 Sokol H, Galperine T, Kapel N, Bourlioux P, Seksik P, Barbut F, Scanzi J, Chast F, Batista R, Joly F, Joly AC, Collignon A, Guery B, Beaugerie L; French Group of Faecal microbiota Transplantation (FGFT). Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation. Dig Liver Dis 2016;48:242-7. [PMID: 26433619 DOI: 10.1016/j.dld.2015.08.017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
442 Manea E, Sojo-Dorado J, Jipa RE, Benea SN, Rodríguez-Baño J, Hristea A. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect 2018;24:180-4. [PMID: 28642147 DOI: 10.1016/j.cmi.2017.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
443 Rizzatti G, Ianiro G, Gasbarrini A. Antibiotic and Modulation of Microbiota: A New Paradigm? Journal of Clinical Gastroenterology 2018;52:S74-7. [DOI: 10.1097/mcg.0000000000001069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
444 Lin C, Wan J, Lu Y, Zhang H, Chen X, Su Y, Zhu W. Active bacterial communities of pig fecal microbiota transplantation suspension prepared and preserved under different conditions. AMB Express 2019;9:63. [PMID: 31076926 DOI: 10.1186/s13568-019-0787-4] [Reference Citation Analysis]
445 Ianiro G, Bibbò S, Porcari S, Settanni CR, Giambò F, Curta AR, Quaranta G, Scaldaferri F, Masucci L, Sanguinetti M, Gasbarrini A, Cammarota G. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes 2021;13:1994834. [PMID: 34709989 DOI: 10.1080/19490976.2021.1994834] [Reference Citation Analysis]
446 Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017;46:171-185. [PMID: 28164849 DOI: 10.1016/j.gtc.2016.09.012] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 19.3] [Reference Citation Analysis]
447 Erikstrup LT, Aarup M, Hagemann-Madsen R, Dagnaes-Hansen F, Kristensen B, Olsen KE, Fuursted K. Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. BMJ Open Gastroenterol 2015;2:e000038. [PMID: 26568840 DOI: 10.1136/bmjgast-2015-000038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
448 Asano S, Katsura M. Determining the optimal surgical timing of fulminant Clostridium difficile colitis by using four objective factors and computed tomography findings: A case report. Int J Surg Case Rep 2021;80:105633. [PMID: 33609944 DOI: 10.1016/j.ijscr.2021.02.019] [Reference Citation Analysis]
449 Yoo IY, Song DJ, Huh HJ, Lee NY. Simultaneous Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxin A/B: Comparison of the C. DIFF QUIK CHEK COMPLETE and RIDASCREEN Assays. Ann Lab Med 2019;39:214-7. [PMID: 30430786 DOI: 10.3343/alm.2019.39.2.214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
450 Sbeit W, Kadah A, Shahin A, Abed N, Haddad H, Jabbour A, Said Ahmad H, Pellicano R, Khoury T, Mari A. Predictors of in-hospital mortality among patients with clostridium difficile infection: a multicenter study. Minerva Med 2021;112:124-9. [PMID: 33205642 DOI: 10.23736/S0026-4806.20.07139-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
451 Alukal J, Dutta SK, Surapaneni BK, Le M, Tabbaa O, Phillips L, Mattar MC. Safety and efficacy of fecal microbiota transplant in 9 critically ill patients with severe and complicated Clostridium difficile infection with impending colectomy. J Dig Dis 2019;20:301-7. [DOI: 10.1111/1751-2980.12750] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
452 Shah S, Ereshefsky B, Pontiggia L, Cawley M. Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection. Hosp Pharm 2019;54:294-9. [PMID: 31555004 DOI: 10.1177/0018578718787439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
453 Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, Scharl M. Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2017;29:322-330. [PMID: 27879485 DOI: 10.1097/meg.0000000000000783] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
454 Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Reference Citation Analysis]
455 Peri R, Aguilar RC, Tüffers K, Erhardt A, Link A, Ehlermann P, Angeli W, Frank T, Storr M, Glück T, Sturm A, Rosien U, Tacke F, Bachmann O, Solbach P, Stallmach A, Goeser F, Vehreschild MJ; German Clinical Microbiome Study Group (GCMSG). The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany. United European Gastroenterol J 2019;7:716-22. [PMID: 31210950 DOI: 10.1177/2050640619839918] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
456 Chen C, Chen Y, Liou J, Wu M; for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. From germ theory to germ therapy. Kaohsiung J Med Sci 2019;35:73-82. [DOI: 10.1002/kjm2.12011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
457 Scott LJ. Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection. Drugs 2013;73:1733-47. [DOI: 10.1007/s40265-013-0134-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
458 Vidović K, Bogdanić N, Balen Topić M. Clostridioides difficile infection treatment guidelines adherence and comparison of treatment outcomes of the first, non-severe disease episode between oral metronidazole and vancomycin group: a single tertiary center retrospective study. Infect Dis (Lond) 2019;51:554-7. [PMID: 31081416 DOI: 10.1080/23744235.2019.1602285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
459 Papic N, Maric LS, Vince A. Efficacy of oral vancomycin in primary prevention of Clostridium Difficile infection in elderly patients treated with systemic antibiotic therapy. Infect Dis (Lond) 2018;50:483-6. [PMID: 29323607 DOI: 10.1080/23744235.2018.1425551] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
460 Mathias F, Curti C, Montana M, Bornet C, Vanelle P. Management of adult Clostridium difficile digestive contaminations: a literature review. Eur J Clin Microbiol Infect Dis 2019;38:209-31. [PMID: 30498879 DOI: 10.1007/s10096-018-3419-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
461 Kosai K, Iwanaga Y, Akamatsu N, Okada Y, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K. Performance evaluation of the Verigene®Clostridium difficile nucleic acid test, an automated multiplex molecular testing system for detection of C. difficile toxin. J Infect Chemother 2017;23:674-7. [PMID: 28751156 DOI: 10.1016/j.jiac.2017.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
462 Krutova M, Zouharova M, Matejkova J, Tkadlec J, Krejčí J, Faldyna M, Nyc O, Bernardy J. The emergence of Clostridium difficile PCR ribotype 078 in piglets in the Czech Republic clusters with Clostridium difficile PCR ribotype 078 isolates from Germany, Japan and Taiwan. International Journal of Medical Microbiology 2018;308:770-5. [DOI: 10.1016/j.ijmm.2018.05.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
463 Alimolaei M, Rahimi HR, Ezatkhah M, Shamsaddini Bafti M, Afzali S. Prevalence, characteristics and antimicrobial susceptibility patterns of Clostridioides difficile isolated from hospitals in Iran. J Glob Antimicrob Resist 2019;19:22-7. [PMID: 30825696 DOI: 10.1016/j.jgar.2019.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
464 Nanayakkara D, Nanda N. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2017;22:314-9. [PMID: 28542111 DOI: 10.1097/MOT.0000000000000430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol 2021;14:17562848211018654. [PMID: 34104214 DOI: 10.1177/17562848211018654] [Reference Citation Analysis]
466 Zilberman-Itskovich S, Youngster I, Lazarovitch T, Bondarenco M, Toledano L, Kachlon Y, Mengesha B, Strul N, Zaidenstein R, Marchaim D. Potential impact of removing metronidazole from treatment armamentarium of mild acute Clostridioides difficile infection. Future Microbiol 2019;14:1489-95. [PMID: 31913060 DOI: 10.2217/fmb-2019-0157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
467 . Faecal microbiota transplantation. Drug Ther Bull 2014;52:141-4. [PMID: 25505015 DOI: 10.1136/dtb.2014.12.0298] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
468 Bouza E, Alcalá L, Marín M, Valerio M, Reigadas E, Muñoz P, González-del Vecchio M, de Egea V. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. Eur J Clin Microbiol Infect Dis 2017;36:1777-86. [DOI: 10.1007/s10096-017-2991-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
469 Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. The Lancet Infectious Diseases 2018;18:1035-44. [DOI: 10.1016/s1473-3099(18)30285-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
470 Srikhanta YN, Hutton ML, Awad MM, Drinkwater N, Singleton J, Day SL, Cunningham BA, Mcgowan S, Lyras D. Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection. Nat Microbiol 2019;4:2237-45. [DOI: 10.1038/s41564-019-0519-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
471 Duarte-Chavez R, Wojda TR, Zanders TB, Geme B, Fioravanti G, Stawicki SP. Early Results of Fecal Microbial Transplantation Protocol Implementation at a Community-based University Hospital. J Glob Infect Dis 2018;10:47-57. [PMID: 29910564 DOI: 10.4103/jgid.jgid_145_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
472 Abughanimeh O, Qasrawi A, Kaddourah O, Al Momani L, Abu Ghanimeh M. Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment. Hosp Pract (1995) 2018;46:266-77. [PMID: 30296190 DOI: 10.1080/21548331.2018.1533673] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
473 Kujawa-Szewieczek A, Adamczak M, Kwiecień K, Dudzicz S, Gazda M, Więcek A. The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics. Nutrients 2015;7:10179-88. [PMID: 26690209 DOI: 10.3390/nu7125526] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
474 Peng Z, Ling L, Stratton CW, Li C, Polage CR, Wu B, Tang YW. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7:15. [PMID: 29434201 DOI: 10.1038/s41426-017-0019-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 12.5] [Reference Citation Analysis]
475 Mullish BH, Quraishi MN, Segal JP, Ianiro G, Iqbal TH. The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterol 2021;12:118-27. [PMID: 33613943 DOI: 10.1136/flgastro-2019-101376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
476 Reveles KR, Lawson KA, Mortensen EM, Pugh MJV, Koeller JM, Argamany JR, Frei CR. National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014. PLoS One 2017;12:e0189227. [PMID: 29216276 DOI: 10.1371/journal.pone.0189227] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
477 Jin SJ, Seo KH, Wi YM. The effect of concomitant use of systemic antibiotics in patients with Clostridium difficile infection receiving metronidazole therapy. Epidemiol Infect 2018;146:558-64. [PMID: 29493484 DOI: 10.1017/S0950268818000390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
478 Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, Bourrier A, Le Gall G, Lalande V, De Rougemont A, Kirchgesner J, Daguenel A, Cachanado M, Rousseau A, Drouet É, Rosenzwajg M, Hagege H, Dray X, Klatzman D, Marteau P, Beaugerie L, Simon T; Saint-Antoine IBD Network. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome 2020;8:12. [PMID: 32014035 DOI: 10.1186/s40168-020-0792-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 25.0] [Reference Citation Analysis]
479 Reigadas E, Alcalá L, Marín M, Martin A, Muñoz P, Bouza E; Spanish C. difficile Toxin Cycle Study Group. Prediction of poor outcome in Clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycle. Anaerobe 2020;61:102079. [PMID: 31356959 DOI: 10.1016/j.anaerobe.2019.102079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
480 Jørgensen SM, Hansen MM, Erikstrup C, Dahlerup JF, Hvas CL. Faecal microbiota transplantation: establishment of a clinical application framework. European Journal of Gastroenterology & Hepatology 2017;29:e36-45. [DOI: 10.1097/meg.0000000000000958] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
481 Novakova E, Stofkova Z, Sadlonova V, Hleba L. Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample. Antibiotics (Basel) 2021;10:1035. [PMID: 34572617 DOI: 10.3390/antibiotics10091035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
482 Olesen SW, Gerardin Y. Re-Evaluating the Evidence for Faecal Microbiota Transplantation ‘Super-Donors’ in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2021;15:453-61. [DOI: 10.1093/ecco-jcc/jjaa170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
483 Aptekorz M, Szczegielniak A, Wiechuła B, Harmanus C, Kuijper E, Martirosian G. Occurrence of Clostridium difficile ribotype 027 in hospitals of Silesia, Poland. Anaerobe 2017;45:106-13. [PMID: 28216085 DOI: 10.1016/j.anaerobe.2017.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
484 Krutova M, Matejkova J, Kuijper EJ, Drevinek P, Nyc O; Czech Clostridium difficile study group. Clostridium difficile PCR ribotypes 001 and 176 – the common denominator of C. difficile infection epidemiology in the Czech Republic, 2014. Eurosurveillance 2016;21. [DOI: 10.2807/1560-7917.es.2016.21.29.30296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
485 Saïdani N, Lagier JC, Cassir N, Million M, Baron S, Dubourg G, Eldin C, Kerbaj J, Valles C, Raoult D, Brouqui P. Faecal microbiota transplantation shortens the colonisation period and allows re-entry of patients carrying carbapenamase-producing bacteria into medical care facilities. Int J Antimicrob Agents 2019;53:355-61. [PMID: 30472293 DOI: 10.1016/j.ijantimicag.2018.11.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
486 Kim HN, Kim H, Moon HW, Hur M, Yun YM. Toxin positivity and tcdB gene load in broad-spectrum Clostridium difficile infection. Infection 2018;46:113-7. [PMID: 29218569 DOI: 10.1007/s15010-017-1108-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
487 Sahra S, Abureesh M, Amarnath S, Alkhayyat M, Badran R, Jahangir A, Gumaste V. Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States. World J Hepatol 2021; 13(8): 926-938 [PMID: 34552699 DOI: 10.4254/wjh.v13.i8.926] [Reference Citation Analysis]
488 Lavallée C, Labbé AC, Talbot JD, Alonso CD, Marr KA, Cohen S, Laverdière M, Dufresne SF. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada. Transpl Infect Dis 2017;19. [PMID: 27943498 DOI: 10.1111/tid.12648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
489 Brinda BJ, Pasikhova Y, Quilitz RE, Thai CM, Greene JN. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections. J Hosp Infect 2017;95:426-32. [PMID: 28153556 DOI: 10.1016/j.jhin.2016.12.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
490 Solanky D, Pardi DS, Loftus EV, Khanna S. Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis 2019;25:610-9. [PMID: 30260451 DOI: 10.1093/ibd/izy291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
491 Chen T, Zhou Q, Zhang D, Jiang F, Wu J, Zhou J, Zheng X, Chen Y. Effect of Faecal Microbiota Transplantation for Treatment of Clostridium difficile Infection in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Cohort Studies. Journal of Crohn's and Colitis 2018;12:710-7. [DOI: 10.1093/ecco-jcc/jjy031] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
492 Guery B, Menichetti F, Anttila V, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-fabrega JA, Cornely OA, Vehreschild MJGT. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. The Lancet Infectious Diseases 2018;18:296-307. [DOI: 10.1016/s1473-3099(17)30751-x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
493 Ma H, Zhang L, Zhang Y, Liu Y, He Y, Guo L. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. Infect Drug Resist. 2019;12:1047-1054. [PMID: 31118710 DOI: 10.2147/idr.s194715] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
494 Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore D, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Williams HR, Goldenberg SD. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. J Hosp Infect. 2018;100 Suppl 1:S1-S31. [PMID: 30173851 DOI: 10.1016/j.jhin.2018.07.037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
495 Antonara S, Leber AL. Diagnosis of Clostridium difficile Infections in Children. J Clin Microbiol 2016;54:1425-33. [PMID: 26912759 DOI: 10.1128/JCM.03014-15] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
496 Roubaud-Baudron C, Ruiz VE, Swan AM Jr, Vallance BA, Ozkul C, Pei Z, Li J, Battaglia TW, Perez-Perez GI, Blaser MJ. Long-Term Effects of Early-Life Antibiotic Exposure on Resistance to Subsequent Bacterial Infection. mBio 2019;10:e02820-19. [PMID: 31874917 DOI: 10.1128/mBio.02820-19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
497 Kobayashi K, Sekiya N, Ainoda Y, Kurai H, Imamura A. Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study. Eur J Clin Microbiol Infect Dis 2017;36:1947-53. [PMID: 28577158 DOI: 10.1007/s10096-017-3018-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
498 Bang BW, Park JS, Kim HK, Shin YW, Kwon KS, Kwon HY, Baek JH, Lee JS. Fecal Microbiota Transplantation for Refractory and Recurrent Clostridium difficile Infection: A Case Series of Nine Patients. Korean J Gastroenterol 2017;69:226-31. [PMID: 28449424 DOI: 10.4166/kjg.2017.69.4.226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
499 Lawler AJ, Lambert PA, Worthington T. A Revised Understanding of Clostridioides difficile Spore Germination. Trends in Microbiology 2020;28:744-52. [DOI: 10.1016/j.tim.2020.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
500 Eckmann C, Lyon S. ECCMID 2016: addressing the burden of recurrent Clostridium difficile infections. Future Microbiol 2016;11:1217-21. [PMID: 27679929 DOI: 10.2217/fmb-2016-0154] [Reference Citation Analysis]
501 Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother. 2015;21:230-237. [PMID: 25703532 DOI: 10.1016/j.jiac.2015.01.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
502 Stalder T, Kapel N, Diaz S, Grenouillet F, Koch S, Limat S, Daval F, Vuitton L, Nerich V. A systematic review of economic evaluation in fecal microbiota transplantation. Infect Control Hosp Epidemiol 2020;41:458-66. [DOI: 10.1017/ice.2019.371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
503 Czepiel J, Biesiada G, Pitera E, Wołkow PP, Michalak M, Garlicki A. Decreased Expression of the High Mobility Group Box 1 (HMGB1) Gene in Peripheral Blood in Patients with Mild or Moderate Clostridioides difficile Infection. Microorganisms 2020;8:E1217. [PMID: 32796569 DOI: 10.3390/microorganisms8081217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
504 Vieira AT, Fukumori C, Ferreira CM. New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clin Transl Immunology 2016;5:e87. [PMID: 27757227 DOI: 10.1038/cti.2016.38] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
505 Davies KA, Planche T, Wilcox MH. The predictive value of quantitative nucleic acid amplification detection of Clostridium difficile toxin gene for faecal sample toxin status and patient outcome. PLoS One 2018;13:e0205941. [PMID: 30517094 DOI: 10.1371/journal.pone.0205941] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
506 Correa-Martínez CL, Hagemeier NCJ, Froböse NJ, Kampmeier S. Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci. Pharmaceuticals (Basel) 2021;14:1066. [PMID: 34832848 DOI: 10.3390/ph14111066] [Reference Citation Analysis]
507 Olmedo M, Alcalá L, Valerio M, Marín M, Onori R, Reigadas E, Muñoz P, Bouza E. Three different patterns of positive Clostridium difficile laboratory tests. A comparison of clinical behavior. Diagn Microbiol Infect Dis 2020;97:115050. [PMID: 32482380 DOI: 10.1016/j.diagmicrobio.2020.115050] [Reference Citation Analysis]
508 Terveer EM, van Gool T, Ooijevaar RE, Sanders IMJG, Boeije-Koppenol E, Keller JJ, Bart A, Kuijper EJ; Netherlands Donor Feces Bank (NDFB) Study Group. Human Transmission of Blastocystis by Fecal Microbiota Transplantation Without Development of Gastrointestinal Symptoms in Recipients. Clin Infect Dis 2020;71:2630-6. [PMID: 31728525 DOI: 10.1093/cid/ciz1122] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
509 Di Bella S, Nisii C, Petrosillo N. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature. International Journal of Antimicrobial Agents 2015;46:8-12. [DOI: 10.1016/j.ijantimicag.2015.03.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
510 Schäffler H, Breitrück A. Clostridium difficile - From Colonization to Infection. Front Microbiol 2018;9:646. [PMID: 29692762 DOI: 10.3389/fmicb.2018.00646] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 13.8] [Reference Citation Analysis]
511 Zhang X, Wang Y, Li X, Hu H, Liu H, Li D, Xiao Y, Zhang T. Safety of fecal microbiota transplantation in chinese children: A single-center retrospective study. WJCC 2018;6:1121-7. [DOI: 10.12998/wjcc.v6.i161.1121] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
512 Prechter F, Stallmach A. [Clostridium difficile in the intensive care unit]. Med Klin Intensivmed Notfmed 2020;115:81-7. [PMID: 29995234 DOI: 10.1007/s00063-018-0459-1] [Reference Citation Analysis]
513 Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk Factors for Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018;24:5000-5007. [PMID: 30020891 DOI: 10.12659/msm.911308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
514 Suarez-Carantoña C, Rodriguez-Torres A, Viteri-Noel A, Pintado V, Garcia-Fernandez S, Mora-Pimentel D, Escudero-Sanchez R, Martin-Jusdado F, Moreno S, Cobo J. Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile. J Clin Med 2021;10:1627. [PMID: 33921309 DOI: 10.3390/jcm10081627] [Reference Citation Analysis]
515 Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 2020;52:12-20. [PMID: 31801387 DOI: 10.1080/07853890.2019.1701703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
516 Cataldo MA, Granata G, Petrosillo N. Clostridium difficile infection: new approaches to prevention, non-antimicrobial treatment, and stewardship. Expert Rev Anti Infect Ther 2017;15:1027-40. [PMID: 28980505 DOI: 10.1080/14787210.2017.1387535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
517 Catho G, Huttner BD. Strategies for the eradication of extended-spectrum beta-lactamase or carbapenemase-producing Enterobacteriaceae intestinal carriage. Expert Rev Anti Infect Ther 2019;17:557-69. [PMID: 31313610 DOI: 10.1080/14787210.2019.1645007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
518 Ianiro G, Porcari S, Bibbò S, Giambò F, Quaranta G, Masucci L, Sanguinetti M, Gasbarrini A, Cammarota G. Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. Dig Liver Dis 2021:S1590-8658(21)00195-X. [PMID: 34030988 DOI: 10.1016/j.dld.2021.04.009] [Reference Citation Analysis]
519 Abreu Y Abreu AT, Velarde-Ruiz Velasco JA, Zavala-Solares MR, Remes-Troche JM, Carmona-Sánchez RI, Aldana-Ledesma JM, Camacho-Ortiz A, Contreras-Omaña R, Díaz-Seoane R, Elizondo-Vázquez CT, Garza-González E, Grajales-Figueroa G, Gómez-Escudero O, Jacobo-Karam JS, Morales-Arámbula M, Olivares-Guzmán LO, Sifuentes-Osornio J, Siu-Moguel AG, Soto-Solís R, Valdovinos-García LR, Valdovinos-Díaz MA, Vázquez-Elizondo G, Lazo-de la Vega Jasso SA. Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed) 2019;84:204-19. [PMID: 30987771 DOI: 10.1016/j.rgmx.2018.12.001] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
520 Daniels LM, Kufel WD. Clinical review of Clostridium difficile infection: an update on treatment and prevention. Expert Opin Pharmacother 2018;19:1759-69. [PMID: 30220230 DOI: 10.1080/14656566.2018.1524872] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
521 Shamriz S, Ofoghi H. Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant. BMC Bioinformatics 2016;17:71. [PMID: 26851942 DOI: 10.1186/s12859-016-0918-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
522 Hammeken LH, Baunwall SMD, Hvas CL, Ehlers LH. Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review. Health Econ Rev 2021;11:3. [PMID: 33439367 DOI: 10.1186/s13561-021-00301-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
523 Krutova M, Capek V, Nycova E, Vojackova S, Balejova M, Geigerova L, Tejkalova R, Havlinova L, Vagnerova I, Cermak P, Ryskova L, Jezek P, Zamazalova D, Vesela D, Kucharova A, Nemcova D, Curdova M, Nyc O, Drevinek P. The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients. Antimicrob Resist Infect Control 2020;9:98. [PMID: 32605598 DOI: 10.1186/s13756-020-00765-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
524 Hota SS, Sales V, Tomlinson G, Salpeter MJ, Mcgeer A, Coburn B, Guttman DS, Low DE, Poutanen SM. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial. Clinical Infectious Diseases 2017;64:265-71. [DOI: 10.1093/cid/ciw731] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 16.2] [Reference Citation Analysis]
525 Dudzicz S, Kujawa-Szewieczek A, Kwiecień K, Więcek A, Adamczak M. Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward-Results of One Year Extended Study. Nutrients 2018;10:E1574. [PMID: 30355985 DOI: 10.3390/nu10111574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
526 Brechmann T, Swol J, Knop-Hammad V, Willert J, Aach M, Cruciger O, Schmiegel W, Schildhauer TA, Hamsen U. Complicated fecal microbiota transplantation in a tetraplegic patient with severe Clostridium difficile infection. World J Gastroenterol 2015; 21(12): 3736-3740 [PMID: 25834343 DOI: 10.3748/wjg.v21.i12.3736] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
527 Chaar A, Feuerstadt P. Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211011953. [PMID: 33995583 DOI: 10.1177/17562848211011953] [Reference Citation Analysis]
528 Lübbert C. Antimicrobial therapy of acute diarrhoea: a clinical review. Expert Rev Anti Infect Ther 2016;14:193-206. [PMID: 26641310 DOI: 10.1586/14787210.2016.1128824] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
529 Chen HL, Zeng YB, Zhang ZY, Kong CY, Zhang SL, Li ZM, Huang JT, Xu YY, Mao YQ, Cai PR, Han B, Wang WQ, Wang LS. Gut and Cutaneous Microbiome Featuring Abundance of Lactobacillus reuteri Protected Against Psoriasis-Like Inflammation in Mice. J Inflamm Res 2021;14:6175-90. [PMID: 34853526 DOI: 10.2147/JIR.S337031] [Reference Citation Analysis]
530 Alonso CD, Papamichael K, Sprague R, Barrett C, Gonzales-Luna AJ, Daugherty K, Garey KW, Villafuerte-Gálvez J, Xu H, Lin Q, Wang L, Chen X, Pollock NR, Kelly CP. Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection. Open Forum Infect Dis 2021;8:ofab286. [PMID: 34258317 DOI: 10.1093/ofid/ofab286] [Reference Citation Analysis]
531 Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, Hota S. Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection. PLoS One 2016;11:e0149521. [PMID: 26901316 DOI: 10.1371/journal.pone.0149521] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
532 Alcalá-hernández L, Mena-ribas A, Niubó-bosh J, Marín-arriaza M. Diagnóstico microbiológico de la infección por Clostridium difficile. Enfermedades Infecciosas y Microbiología Clínica 2016;34:595-602. [DOI: 10.1016/j.eimc.2015.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
533 Saha S, Khanna S. Management of Clostridioides difficile colitis: insights for the gastroenterologist. Therap Adv Gastroenterol 2019;12:1756284819847651. [PMID: 31105766 DOI: 10.1177/1756284819847651] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
534 Högenauer C, Mahida Y, Stallmach A, Marteau P, Rydzewska G, Ivashkin V, Gargalianos-Kakolyris P, Michon I, Adomakoh N, Georgopali A, Tretter R, Karas A, Reinisch W. Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE). J Antimicrob Chemother 2018;73:3430-41. [PMID: 30260412 DOI: 10.1093/jac/dky368] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
535 Erb S, Frei R, Strandén AM, Dangel M, Tschudin-Sutter S, Widmer AF. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients. Clin Microbiol Infect 2015;21:998.e9-998.e15. [PMID: 26232535 DOI: 10.1016/j.cmi.2015.07.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
536 Prechter F, Katzer K, Bauer M, Stallmach A. Sleeping with the enemy: Clostridium difficile infection in the intensive care unit. Crit Care 2017;21:260. [PMID: 29058580 DOI: 10.1186/s13054-017-1819-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
537 Esteban-Vasallo MD, Naval Pellicer S, Domínguez-Berjón MF, Cantero Caballero M, Asensio Á, Saravia G, Astray-Mochales J. Age and gender differences in Clostridium difficile-related hospitalization trends in Madrid (Spain) over a 12-year period. Eur J Clin Microbiol Infect Dis 2016;35:1037-44. [PMID: 27056555 DOI: 10.1007/s10096-016-2635-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
538 Holt HM, Danielsen TK, Justesen US. Routine disc diffusion antimicrobial susceptibility testing of Clostridium difficile and association with PCR ribotype 027. Eur J Clin Microbiol Infect Dis 2015;34:2243-6. [PMID: 26319148 DOI: 10.1007/s10096-015-2475-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
539 Hagel S, Fischer A, Ehlermann P, Frank T, Tueffers K, Sturm A, Link A, Demir M, Siebenhaar A, Storr M, Glueck T, Siegel E, Solbach P, Goeser F, Koelbel CB, Lohse A, Luebbert C, Kandzi U, Maier M, Schuerle S, Lerch MM, Tacke D, Cornely OA, Stallmach A, Vehreschild M; German Clinical Microbiome Study Group (GCMSG). Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection. Dtsch Arztebl Int 2016;113:583-9. [PMID: 27658471 DOI: 10.3238/arztebl.2016.0583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
540 Palmieri LJ, Rainteau D, Sokol H, Beaugerie L, Dior M, Coffin B, Humbert L, Eguether T, Bado A, Hoys S, Janoir C, Duboc H. Inhibitory Effect of Ursodeoxycholic Acid on Clostridium difficile Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. Front Microbiol 2018;9:2849. [PMID: 30524414 DOI: 10.3389/fmicb.2018.02849] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
541 . Clostridium difficile Relapse Secondary to Medication Access Issue. AORN J 2015;102:108, 63. [PMID: 26119615 DOI: 10.1016/j.aorn.2015.04.017] [Reference Citation Analysis]
542 Dinh A, Le Monnier A, Emery C, Alami S, Torreton É, Duburcq A, Barbier F. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study. Eur J Clin Microbiol Infect Dis 2019;38:1297-305. [PMID: 30941532 DOI: 10.1007/s10096-019-03552-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
543 von Müller L, Mock M, Halfmann A, Stahlmann J, Simon A, Herrmann M. Epidemiology of Clostridium difficile in Germany based on a single center long-term surveillance and German-wide genotyping of recent isolates provided to the advisory laboratory for diagnostic reasons. Int J Med Microbiol. 2015;305:807-813. [PMID: 26341328 DOI: 10.1016/j.ijmm.2015.08.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
544 Hung Y, Lee J, Lin H, Chiu C, Wu J, Liu H, Huang I, Tsai P, Ko W. Perceptions of Clostridium difficile infections among infection control professionals in Taiwan. Journal of Microbiology, Immunology and Infection 2017;50:521-6. [DOI: 10.1016/j.jmii.2017.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
545 Rao K, Higgins PD. Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1744-54. [PMID: 27120571 DOI: 10.1097/MIB.0000000000000793] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
546 Leffad M, Raoult D. CMI editorial report, 2016. Clin Microbiol Infect 2016;22:1-7. [PMID: 26551843 DOI: 10.1016/j.cmi.2015.10.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
547 Mateu L, Fernández-Rivas G, Sopena N. Diagnosis and treatment of Clostridioides difficile infection. Med Clin (Barc) 2020;155:30-5. [PMID: 32430207 DOI: 10.1016/j.medcli.2020.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
548 Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings 2020;95:758-69. [DOI: 10.1016/j.mayocp.2019.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
549 van Eijk E, Boekhoud IM, Kuijper EJ, Bos-Sanders IMJG, Wright G, Smits WK. Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile. Antimicrob Agents Chemother 2019;63:e01363-18. [PMID: 30455241 DOI: 10.1128/AAC.01363-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
550 Landaburu MF, López Daneri GA, Relloso S, Zarlenga LJ, Vinante MA, Mujica MT. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. Rev Argent Microbiol 2020;52:27-30. [PMID: 31262611 DOI: 10.1016/j.ram.2019.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
551 Legaria MC, Rollet R, Di Martino A, Castello L, Barberis C, Rossetti MA, Guardati MC, Fernández Canigia L, Carloni G, Litterio M, Rocchi M, Anchart EG, Trejo FM, Minnaard J, Klajn D, Predari SC. Detection of toxigenic Clostridioides [Clostridium] difficile: Usefulness of two commercially available enzyme immunoassays and a PCR assay on stool samples and stool isolates. Rev Argent Microbiol 2018;50:36-44. [PMID: 28988901 DOI: 10.1016/j.ram.2017.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
552 Alexander T, Snowden JA, Burman J, Chang HD, Del Papa N, Farge D, Lindsay JO, Malard F, Muraro PA, Nitti R, Salas A, Sharrack B, Mohty M, Greco R. Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. Front Oncol 2021;11:722436. [PMID: 34745944 DOI: 10.3389/fonc.2021.722436] [Reference Citation Analysis]
553 Zhang Y, Sun J, Zhang J, Liu Y, Guo L. Enzyme Inhibitor Antibiotics and Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018;24:8781-8788. [PMID: 30512009 DOI: 10.12659/msm.913739] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
554 Escudero-Sánchez R, Valencia-Alijo A, Cuéllar Tovar S, Merino-de Lucas E, García Fernández S, Gutiérrez-Rojas Á, Ramos-Martínez A, Salavert Lletí M, Castro Hernández I, Giner L, Cobo J. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes. Infection 2021;49:475-82. [PMID: 33417171 DOI: 10.1007/s15010-020-01567-5] [Reference Citation Analysis]
555 Ianiro G, Valerio L, Masucci L, Pecere S, Bibbò S, Quaranta G, Posteraro B, Currò D, Sanguinetti M, Gasbarrini A, Cammarota G. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect 2017;23:337.e1-3. [PMID: 28057560 DOI: 10.1016/j.cmi.2016.12.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
556 McCreery G, Jones PM, Kidane B, DeMelo V, Mele T; ERASE C. difficile (Early Rescue from Acute SEvere Clostridium difficile) Trials Group. Polyethylene glycol intestinal lavage in addition to usual antibiotic treatment for severe Clostridium difficile colitis: a randomised controlled pilot study. BMJ Open 2017;7:e016803. [PMID: 28760801 DOI: 10.1136/bmjopen-2017-016803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
557 Jamal WY, Rotimi VO. Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait. PLoS One 2016;11:e0161411. [PMID: 27536994 DOI: 10.1371/journal.pone.0161411] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
558 Deeks ED. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence. Drugs 2017;77:1657-63. [PMID: 28865041 DOI: 10.1007/s40265-017-0809-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
559 Sandlund J, Davies K, Wilcox MH. Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic Accuracy. J Clin Microbiol 2020;58:e01913-19. [PMID: 32269098 DOI: 10.1128/JCM.01913-19] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
560 Freeman J, Pilling S, Vernon J, Wilcox MH. In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread. Antimicrob Agents Chemother 2017;61:e02077-16. [PMID: 27993853 DOI: 10.1128/AAC.02077-16] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
561 Ianiro G, Maida M, Burisch J, Simonelli C, Hold G, Ventimiglia M, Gasbarrini A, Cammarota G. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis. United European Gastroenterol J. 2018;6:1232-1244. [PMID: 30288286 DOI: 10.1177/2050640618780762] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 20.0] [Reference Citation Analysis]
562 Robak K, Zambonelli J, Bilinski J, Basak GW. Diarrhea after allogeneic stem cell transplantation: beyond graft-versus-host disease. Eur J Gastroenterol Hepatol. 2017;29:495-502. [PMID: 28067684 DOI: 10.1097/meg.0000000000000833] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
563 Popescu GA, Serban R, Pistol A, Niculcea A, Preda A, Lemeni D, Macovei IS, Tălăpan D, Rafila A, Florea D. The Recent Emergence of Clostridium difficile Infection in Romanian Hospitals is Associated with a High Prevalence of Polymerase Chain Reaction Ribotype 027. Balkan Med J 2018;35:191-5. [PMID: 29188783 DOI: 10.4274/balkanmedj.2017.0400] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
564 Fang H, Fu L, Li X, Lu C, Su Y, Xiong K, Zhang L. Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study. Microb Cell Fact 2021;20:18. [PMID: 33468164 DOI: 10.1186/s12934-021-01513-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
565 Orden C, Blanco JL, Álvarez-Pérez S, Garcia-Sancho M, Rodriguez-Franco F, Sainz A, Villaescusa A, Harmanus C, Kuijper E, Garcia ME. Isolation of Clostridium difficile from dogs with digestive disorders, including stable metronidazole-resistant strains. Anaerobe 2017;43:78-81. [PMID: 27965048 DOI: 10.1016/j.anaerobe.2016.12.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
566 Rodríguez-Martín C, Serrano-Morte A, Sánchez-Muñoz LA, de Santos-Castro PA, Bratos-Pérez MA, Ortiz de Lejarazu-Leonardo R. [Identifying gaps between guidelines and clinical practice in Clostridium difficile infection]. Rev Calid Asist 2016;31:152-8. [PMID: 26708998 DOI: 10.1016/j.cali.2015.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
567 Khanafer N, Blais L, Barbut F, Hirschel B, Vanhems P. Treatment of Clostridium difficile infection in a French university hospital. Scand J Gastroenterol 2015;50:1253-60. [PMID: 25877477 DOI: 10.3109/00365521.2015.1033746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
568 Goldstein EJC, Johnson SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, McFarland LV. Probiotics and prevention of Clostridium difficile infection. Anaerobe 2017;45:114-9. [PMID: 27988389 DOI: 10.1016/j.anaerobe.2016.12.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
569 Couture-Cossette A, Carignan A, Ilangumaran S, Valiquette L. Bezlotoxumab for the prevention of Clostridium difficile recurrence. Expert Opin Biol Ther 2017;17:1439-45. [PMID: 28805081 DOI: 10.1080/14712598.2017.1363886] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
570 Ooijevaar R, van Beurden Y, Terveer E, Goorhuis A, Bauer M, Keller J, Mulder C, Kuijper E. Update of treatment algorithms for Clostridium difficile infection. Clinical Microbiology and Infection 2018;24:452-62. [DOI: 10.1016/j.cmi.2017.12.022] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 15.8] [Reference Citation Analysis]
571 von Eichel-streiber A, Paik W, Knight K, Gisch K, Nadjafi K, Decker C, Bosnjak O, Cheknis A, Johnson S, von Eichel-streiber C. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors. Anaerobe 2016;41:91-103. [DOI: 10.1016/j.anaerobe.2016.07.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
572 Principi N, Gnocchi M, Gagliardi M, Argentiero A, Neglia C, Esposito S. Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem. Microorganisms 2020;8:E1640. [PMID: 33114040 DOI: 10.3390/microorganisms8111640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
573 Shin JY, Ko EJ, Lee SH, Shin JB, Kim SI, Kwon KS, Kim HG, Shin YW, Bang BW. Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation. Intest Res 2016;14:83-8. [PMID: 26884739 DOI: 10.5217/ir.2016.14.1.83] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
574 Ballo O, Kreisel EM, Eladly F, Brunnberg U, Stratmann J, Hunyady P, Hogardt M, Wichelhaus TA, Kempf VAJ, Steffen B, Vehreschild JJ, Vehreschild MJGT, Finkelmeier F, Serve H, Brandts CH. Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy. Ann Hematol 2020;99:2547-53. [PMID: 32974837 DOI: 10.1007/s00277-020-04274-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
575 Crobach MJT, Vernon JJ, Loo VG, Kong LY, Péchiné S, Wilcox MH, Kuijper EJ. Understanding Clostridium difficile Colonization. Clin Microbiol Rev 2018;31:e00021-17. [PMID: 29540433 DOI: 10.1128/CMR.00021-17] [Cited by in Crossref: 86] [Cited by in F6Publishing: 43] [Article Influence: 21.5] [Reference Citation Analysis]
576 Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095. [PMID: 29257353 DOI: 10.1002/14651858.cd006095.pub4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 90] [Article Influence: 15.6] [Reference Citation Analysis]
577 Putot A, Astruc K, Barben J, Mihai AM, Nuss V, Bador J, Putot S, Dipanda M, Laborde C, Vovelle J, Da Silva S, Mazen E, Aho Glélé LS, Manckoundia P. Impact of a Diagnosis-Centered Antibiotic Stewardship on Incident Clostridioides difficile Infections in Older Inpatients: An Observational Study. Antibiotics (Basel) 2020;9:E303. [PMID: 32517086 DOI: 10.3390/antibiotics9060303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
578 Cho JC, Crotty MP, Pardo J. Ridinilazole: a novel antimicrobial for Clostridium difficile infection. Ann Gastroenterol 2019;32:134-40. [PMID: 30837785 DOI: 10.20524/aog.2018.0336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
579 Dorsaz S, Charretier Y, Girard M, Gaïa N, Leo S, Schrenzel J, Harbarth S, Huttner B, Lazarevic V. Changes in Microbiota Profiles After Prolonged Frozen Storage of Stool Suspensions. Front Cell Infect Microbiol 2020;10:77. [PMID: 32185143 DOI: 10.3389/fcimb.2020.00077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
580 Lübbert C, John E, von Müller L. Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int. 2014;111:723-731. [PMID: 25404529 DOI: 10.3238/arztebl.2014.0723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
581 O’grady K, Knight DR, Riley TV. Antimicrobial resistance in Clostridioides difficile. Eur J Clin Microbiol Infect Dis. [DOI: 10.1007/s10096-021-04311-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
582 Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, Gasbarrini A, Cammarota G. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther. 2018;48:152-159. [PMID: 29851107 DOI: 10.1111/apt.14816] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 16.8] [Reference Citation Analysis]
583 Núñez F P, Quera R, Bay C, Thomson P. Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. Gastroenterol Hepatol 2021:S0210-5705(21)00192-8. [PMID: 34118321 DOI: 10.1016/j.gastrohep.2021.05.009] [Reference Citation Analysis]
584 Tariq R, Pardi DS, Bartlett MG, Khanna S. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019;68:1351-1358. [PMID: 30957161 DOI: 10.1093/cid/ciy721] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
585 Tan X, Johnson S. Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'. Anaerobe 2019;60:102092. [PMID: 31472233 DOI: 10.1016/j.anaerobe.2019.102092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
586 Jamal W, Pauline E, Rotimi V. A prospective study of community-associated Clostridium difficile infection in Kuwait: Epidemiology and ribotypes. Anaerobe 2015;35:28-32. [DOI: 10.1016/j.anaerobe.2015.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
587 Alcalá Hernández L, Reigadas Ramírez E, Bouza Santiago E. Infección por Clostridium difficile. Medicina Clínica 2017;148:456-63. [DOI: 10.1016/j.medcli.2017.01.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
588 Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol 2021;116:647-56. [PMID: 33982930 DOI: 10.14309/ajg.0000000000001075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
589 Legenza L, Barnett S, Rose W, Bianchini M, Safdar N, Coetzee R. Epidemiology and outcomes of Clostridium difficile infection among hospitalised patients: results of a multicentre retrospective study in South Africa. BMJ Glob Health 2018;3:e000889. [PMID: 30057799 DOI: 10.1136/bmjgh-2018-000889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
590 Terreni M, Taccani M, Pregnolato M. New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules 2021;26:2671. [PMID: 34063264 DOI: 10.3390/molecules26092671] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
591 Bednarska A, Bursa D, Podlasin R, Paciorek M, Skrzat-Klapaczyńska A, Porowski D, Raczyńska J, Puła J, Krogulec D, Makowiecki M, Horban A. Advanced age and increased CRP concentration are independent risk factors associated with Clostridioides difficile infection mortality. Sci Rep 2020;10:14681. [PMID: 32895405 DOI: 10.1038/s41598-020-71466-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
592 Lai H, Huang C, Cai J, Ye J, She J, Zheng Y, Wang L, Wei Y, Fang W, Wang X, Tang YW, Luo Y, Jin D. Simultaneous detection and characterization of toxigenic Clostridium difficile directly from clinical stool specimens. Front Med 2018;12:196-205. [PMID: 29058256 DOI: 10.1007/s11684-017-0560-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
593 Chopra T, Goldstein EJ, Gorbach SL. Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection. Pharmacotherapy 2016;36:1281-9. [PMID: 27862113 DOI: 10.1002/phar.1863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
594 Chauhan A, Kumar R, Sharma S, Mahanta M, Vayuuru SK, Nayak B, Kumar S, Shalimar. Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study. Dig Dis Sci 2021;66:873-80. [PMID: 32279172 DOI: 10.1007/s10620-020-06246-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
595 Maida M, Mcilroy J, Ianiro G, Cammarota G. Faecal Microbiota Transplantation as Emerging Treatment in European Countries. Adv Exp Med Biol 2018;1050:177-95. [PMID: 29383670 DOI: 10.1007/978-3-319-72799-8_11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
596 Heath RD, Cockerell C, Mankoo R, Ibdah JA, Tahan V. Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders. North Clin Istanb. 2018;5:79-88. [PMID: 29607440 DOI: 10.14744/nci.2017.10692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
597 Spitz C, Mathias F, Péchiné S, Doan THD, Innocent J, Pellissier S, Di Giorgio C, Crozet MD, Janoir C, Vanelle P. 2,4-Disubstituted 5-Nitroimidazoles Potent against Clostridium difficile. ChemMedChem 2019;14:561-9. [PMID: 30644169 DOI: 10.1002/cmdc.201800784] [Reference Citation Analysis]
598 Ünal CM, Steinert M. Novel therapeutic strategies for Clostridium difficile infections. Expert Opin Ther Targets 2016;20:269-85. [PMID: 26565670 DOI: 10.1517/14728222.2016.1090428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
599 Baines SD, Wilcox MH. Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection. Antibiotics (Basel) 2015;4:267-98. [PMID: 27025625 DOI: 10.3390/antibiotics4030267] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
600 Link A, Lachmund T, Schulz C, Weigt J, Malfertheiner P. Endoscopic peroral jejunal fecal microbiota transplantation. Dig Liver Dis 2016;48:1336-9. [PMID: 27575658 DOI: 10.1016/j.dld.2016.08.110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
601 Spigaglia P, Barbanti F, Castagnola E, Bandettini R. Clostridium difficile infection (CDI) in children due to hypervirulent strains PCR-ribotype 027: An emblematic report of two cases. Anaerobe 2015;36:91-3. [PMID: 26385433 DOI: 10.1016/j.anaerobe.2015.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
602 Jazmati N, Kirpal E, Piepenbrock E, Stelzer Y, Vehreschild MJGT, Seifert H. Evaluation of the Use of Rectal Swabs for Laboratory Diagnosis of Clostridium difficile Infection. J Clin Microbiol 2018;56:e00426-18. [PMID: 29720433 DOI: 10.1128/JCM.00426-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
603 Baktash A, Terveer EM, Zwittink RD, Hornung BVH, Corver J, Kuijper EJ, Smits WK. Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. Front Microbiol 2018;9:1242. [PMID: 29946308 DOI: 10.3389/fmicb.2018.01242] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
604 Mosca A, Leclerc M, Hugot JP. Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem? Front Microbiol 2016;7:455. [PMID: 27065999 DOI: 10.3389/fmicb.2016.00455] [Cited by in Crossref: 189] [Cited by in F6Publishing: 179] [Article Influence: 31.5] [Reference Citation Analysis]
605 Cojocariu C, Girleanu I, Trifan A, Olteanu A, Muzica CM, Huiban L, Chiriac S, Singeap AM, Cuciureanu T, Sfarti C, Stanciu C. Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic Clostridium difficile infection? World J Clin Cases 2021; 9(33): 10180-10188 [PMID: 34904088 DOI: 10.12998/wjcc.v9.i33.10180] [Reference Citation Analysis]
606 Moon HW, Kim HN, Hur M, Shim HS, Kim H, Yun YM. Comparison of Diagnostic Algorithms for Detecting Toxigenic Clostridium difficile in Routine Practice at a Tertiary Referral Hospital in Korea. PLoS One 2016;11:e0161139. [PMID: 27532104 DOI: 10.1371/journal.pone.0161139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
607 Fischer M, Sipe B, Cheng YW, Phelps E, Rogers N, Sagi S, Bohm M, Xu H, Kassam Z. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach. Gut Microbes. 2017;8:289-302. [PMID: 28001467 DOI: 10.1080/19490976.2016.1273998] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 14.7] [Reference Citation Analysis]
608 Mizusawa M, Doron S, Gorbach S. Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options. Drugs Aging 2015;32:639-47. [DOI: 10.1007/s40266-015-0289-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
609 Berkefeld A, Berger FK, Gärtner BC, Wantia N, Prinzing A, Laugwitz KL, Busch DH, Rothe K. Clostridioides (Clostridium) difficile Pacemaker Infection. Open Forum Infect Dis 2020;7:ofaa487. [PMID: 33324719 DOI: 10.1093/ofid/ofaa487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
610 Korbmacher M, Fischer S, Landenberger M, Papatheodorou P, Aktories K, Barth H. Human α-Defensin-5 Efficiently Neutralizes Clostridioides difficile Toxins TcdA, TcdB, and CDT. Front Pharmacol 2020;11:1204. [PMID: 32903430 DOI: 10.3389/fphar.2020.01204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
611 Arends S, Defosse J, Diaz C, Wappler F, Sakka SG. Successful treatment of severe Clostridium difficile infection by administration of crushed fidaxomicin via a nasogastric tube in a critically ill patient. Int J Infect Dis 2017;55:27-8. [PMID: 28027991 DOI: 10.1016/j.ijid.2016.12.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
612 Porter R, Fogg C. Faecal microbiota transplantation for Clostridium difficile infection in the United Kingdom. Clinical Microbiology and Infection 2015;21:578-82. [DOI: 10.1016/j.cmi.2015.01.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
613 Bacigalupo A, Metafuni E, Amato V, Marquez Algaba E, Pagano L. Reducing infectious complications after allogeneic stem cell transplant. Expert Rev Hematol 2020;13:1235-51. [PMID: 32996342 DOI: 10.1080/17474086.2020.1831382] [Reference Citation Analysis]
614 Guery B, Georgopali A, Karas A, Kazeem G, Michon I, Wilcox MH, Cornely OA. Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial. J Antimicrob Chemother 2020;75:1014-8. [PMID: 31960058 DOI: 10.1093/jac/dkz549] [Reference Citation Analysis]
615 Woods EC, Wetzel D, Mukerjee M, McBride SM. Examination of the Clostridioides (Clostridium) difficile VanZ ortholog, CD1240. Anaerobe 2018;53:108-15. [PMID: 29940245 DOI: 10.1016/j.anaerobe.2018.06.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
616 Posteraro B, Pea F, Masucci L, Posteraro P, Sanguinetti M. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? Expert Opin Biol Ther 2018;18:469-76. [PMID: 29534621 DOI: 10.1080/14712598.2018.1452908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
617 Hu Y, Xiao HY, He C, Lv NH, Zhu L. Fecal microbiota transplantation as an effective initial therapy for pancreatitis complicated with severe Clostridium difficile infection: A case report. World J Clin Cases 2019; 7(17): 2597-2604 [PMID: 31559298 DOI: 10.12998/wjcc.v7.i17.2597] [Reference Citation Analysis]
618 Reigadas E, Alcalá L, Marín M, Muñoz-pacheco P, Catalán P, Martin A, Bouza E. Clinical significance of direct cytotoxicity and toxigenic culture in Clostridium difficile infection. Anaerobe 2016;37:38-42. [DOI: 10.1016/j.anaerobe.2015.10.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
619 Lin Z, Iqbal Z, Ortiz JF, Khan SA, Jahan N. Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infection: Is it Superior to Other Conventional Methods? Cureus 2020;12:e9653. [PMID: 32923252 DOI: 10.7759/cureus.9653] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
620 Borgia G, Maraolo AE, Foggia M, Buonomo AR, Gentile I. Fecal microbiota transplantation for Clostridium difficile infection: back to the future. Expert Opin Biol Ther. 2015;15:1001-1014. [PMID: 26063385 DOI: 10.1517/14712598.2015.1045872] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
621 Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline : a critical safety review. Expert Opin Drug Saf 2015;14:335-42. [PMID: 25539800 DOI: 10.1517/14740338.2015.997206] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
622 Knafl D, Winhofer Y, Lötsch F, Weisshaar S, Steininger C, Burgmann H, Thalhammer F. Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report. Journal of Hospital Infection 2016;92:296-8. [DOI: 10.1016/j.jhin.2015.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
623 Adelman MW, Woodworth MH, Shaffer VO, Martin GS, Kraft CS. Critical Care Management of the Patient with Clostridioides difficile. Crit Care Med 2021;49:127-39. [PMID: 33156122 DOI: 10.1097/CCM.0000000000004739] [Reference Citation Analysis]
624 Burton HE, Mitchell SA, Watt M. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. Pharmacoeconomics 2017;35:1123-40. [PMID: 28875314 DOI: 10.1007/s40273-017-0540-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
625 Pichenot M, Héquette-Ruz R, Le Guern R, Grandbastien B, Charlet C, Wallet F, Schiettecatte S, Loeuillet F, Guery B, Galperine T. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital. Infection 2017;45:425-31. [PMID: 28120176 DOI: 10.1007/s15010-017-0981-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]